探讨益髓颗粒对免疫性血小板减少性紫癜动物模型的免疫网络调控机制
|
摘要
1.目的
免疫性血小板减少性紫癜(immune thrombocytopenic purpura, ITP)是一种以血小板减少和皮肤粘膜出血为特征的自身免疫性疾病。其发病与免疫失调关系密切,但导致免疫功能异常的调控因素仍未完全阐明。临床上应用糖皮质激素、脾切除术等治疗可使70%以上病例血小板数量维持在安全范围,但还有约30%病例此方案治疗无效,需进一步采用其它治疗措施来维持血小板数量在安全水平,防止严重出血。应用糖皮质激素和脾脏切除术治疗无效的病例为难治性ITP (refractory immune thrombocytopenic purpura, RITP)。本研究用外源性抗体注入小鼠体内免疫的方法建立ITP小鼠模型,用益髓颗粒进行干预研究,观察ITP小鼠外周血血小板、骨髓巨核细胞、细胞因子、脾脏和胸腺细胞凋亡指数及凋亡基因表达、脾脏调节性T细胞等指标进行研究,试图从免疫网络调控角度阐明“益髓颗粒”治疗ITP效应机制。
2.方法
制备豚鼠抗Balb/C小鼠血抗小板血清,予红细胞吸附后备用。造模前将20只Balb/C小鼠依据外周血血小板数随机分正常组、模型组。模型组按照100μ1／20g剂量向小鼠腹腔内注入1：4稀释的GP-APS,隔日一次,造模两周后,检测外周血小板计数、骨髓巨核细胞数量及形态分类,观察胸腺及脾脏病理学改变,以判定疾病模型是否成功。
ITP疾病动物模型建立成功后,按血小板计数将70只Balb/C小鼠随机分为正常组、模型组、醋酸泼尼松治疗组、升血小板胶囊治疗组、益髓颗粒大、中、小剂量治疗组,于造模第8天开始各组均按0.2m1／10g体重分别予生理盐水及治疗药物灌胃,每日1次,共7天。通过观察造模小鼠外周血小板计数、骨髓巨核细胞数量及形态分类、血小板相关抗体、脏器指数及免疫组织器官病理学变化等指标,评价益髓颗粒治疗效果。
在确定疗效后,我们按上述造模方法建立ITP,用大剂量益髓颗粒为治疗药进行干预,用ELISA检测与免疫密切相关的Th1/Th2细胞因子(IFN-y/IL-4)及TGF-β1, TUNEL法及免疫组化法分别检测脾脏和胸腺细胞凋亡指数及凋亡基因Bcl-2、Bax的表达,用流式细胞仪检测脾脏调节性T细胞等指标进行研究,探讨益髓颗粒治疗ITP可能的免疫调控机制。
3.结果
3.1 ITP小鼠模型的建立
GP-APS稀释倍数为1：128时仍成阳性,说明豚鼠血清中已产生了特异性抗体,即豚鼠抗Balb/C小鼠血小板抗体。与正常组及造模前比较,ITP小鼠模型外周血血小板明显降低,差异显著有统计学意义(P<0.05,P<0.01),注射APS后24小时模型小鼠外周血小板数最低。模型组小鼠骨髓巨核细胞总数明显增加,而产板巨核细胞减少,与正常组比较,差异显著有统计学意义(P<0.05,P<0.01)。模型组凝血时间明显延长,与正常组比较,差异显著有统计学意义(P<0.001)。模型组小鼠脾脏指数明显大于正常组,差异显著有统计学意义(P<0.001),胸腺指数与正常组比较差异不显著无统计学意义。
3.2益髓颗粒对ITP小鼠模型治疗作用的实验研究
与模型组比,各治疗组血小板数均比模型组有所升高,差异显著有统计学意义(P<0.01,P<0.001),以益髓颗粒大剂量组和泼尼松组血小板升高明显。益髓颗粒大剂量组不成熟的骨髓巨核细胞增生受到抑制,产板巨核细胞增多,与模型组比较,有统计学意义(P<0.01,P<0.001)；模型组PAIgG水平明显升高低,与正常组比差异显著有统计学意义(P<0.001),经治疗后,益髓颗粒组PAIgG水平明显低于模型组,与正常组比差异不明显无统计学意义。与模型组比,各治疗组脾脏均有所缩小,脾脏指数降低,差异显著有统计学意义(P<0.001),以益髓颗粒大剂量组效果明显。
3.3益髓颗粒对ITP小鼠免疫网络调控机制的实验研究
与正常组相比,模型组小鼠IFN-y水平明显升高,IL-4水平明显降低,IFN-γ/IL-4比值升高,Th1/Th2细胞间失衡,提示ITP小鼠存在细胞免疫功能低下及T细胞亚群漂移,表现为Thl细胞优势；Treg细胞比例、TGF-β1水平明显降低,脾脏淋巴细胞凋亡减少,Bcl-2蛋白表达增多,Bax蛋白表达减少,各组胸腺淋巴细胞凋亡及Bcl-2、Bax蛋白差异不明显无统计学意义。而经治疗后ITP小鼠血清INF-y水平降低,IL-4水平长高,IFN-y/IL-4比值降低,与模型组比较,益髓颗粒治疗组的IFN-y降低,IL-4升高,IFN-γ/IL-4比值接近正常；Treg细胞比例及TGF-β1水平均有所提高,但Treg仍未达到正常水平,与正常组比仍存在差异,而TGF-β1与正常组比差异不明显无统计学意义；益髓颗粒组脾脏淋巴细胞凋亡增多,Bcl-2蛋白表达减少,Bax蛋白表达增多。
4.结论
4.1成功制备了GP-APS,IPT小鼠疾病模型建立成功,模型小鼠外周血小板下降、骨髓巨核细胞增多并伴成熟障碍,与ITP临床表现基本相符。
4.2益髓颗粒能有效恢复ITP小鼠的血小板计数,并能促进骨髓巨核细胞向成熟方向分化,与醋酸泼尼松疗效相当。
4.3 ITP存在细胞免疫功能低下及T细胞亚群漂移,表现为Thl细胞优势,其发病可能与Th1/Th2细胞间细胞因子失衡,Treg细胞及TGF-β1含量降低,淋巴细胞凋亡及Bcl-2、Bax蛋白表达异常等相关。益髓颗粒可能通过调节Th1/Th2细胞间的平衡,促进Treg细胞增殖及TGF-β1分泌,并能调节脾脏淋巴细胞凋亡及凋亡基因Bcl-2、Bax的异常表达,进而调节ITP免疫异常,降低血小板相关抗体,减少血小板破坏,提高血小板数量,促进骨髓巨核细胞向成熟方向分化而达到治疗效果。
1.Objective
Immune thrombotopenic purpura is an autoimmune (ITP) disorder characterized by a low platelet count and mucocutaneous bleeding.A number of features suggest this destruction is immune-mediated,But the exact mechanism of the immune dysfunction, however, is generally not known. More than 70% patients response to treatment with glucocorticoids and splenectomy,but there are about 30% of refractory patients (refractory immune thrombocytopenic purpura, RITP) are defined as those in whom treatment with standard-dose corticosteroids and splenectomy fails and who further therapy because of unsafe platelet counts or clinical bleeding.In this study,ITP mouse model were made by injected exogenous antibodies intraperitoneally guinea pig-antimouse platelet serum (GP-APS) and treated with YiSui granules.Observe the effect of Yisui granules on ITP mouse peripheral blood platelets,bone marrow megakaryocytes,cytokines,spleen and thymus apoptosis index and the apoptotic gene expression,regulatory T cells in the spleen and other factors.Trying to explore Yisui granules effective mechanism on the regulation of immune network in ITP.
2.Methods
Preparation of guinea pig anti-Balb/C mice anti-platelet serum (GP-APS) and red blood cell adsorption and reserved.Twenty Balb/c mice were randomly divided into normal group,model group according to the counts of Peripheral platelet.ITP mouse model were made by injected intraperitoneally 1:4 guinea pig-antimouse platelet serum (GP-APS) at a dose of 100μl/20g every other day.Detect the peripheral platelet counts,bone marrow megakaryocyte counts and morphology classification,observe the pathological changes in thymus and spleen to after two weeks in order to judge whether the model was successful or not.
After ITP mouse model was verified successful,seventy Balb/C mice were were randomly divided into normal group,model group,Prednisolone acetate group,ShengXue XiaoBan capsule and Yisui granules high,medium and low-dosege groups.The 8th day establishing the model,each group were intragastric administration at a dose of 0.2ml/10g·d-1 volume with normal saline and every treated medicine daily for additional one week respectively.Evaluate the therapeutic effect of YiSui granules according to detecting the peripheral platelet counts,blood coagulation time, bone marrow megakaryocyte counts and morphology classificatio,platelet-associated antibodies,the immune organ index and the pathological changes.
After the therapeutic effect of YiSui granule had been determined,the ITP mouse model were established as the methods above-mentioned and treated with high dosage of YiSui granules.Two weeks latter,The levels of immune closely related to Thl/Th2 cytokines (IFN-y and IL-4) and TGF-β1 in peripheral blood serum were detected by ELISA.The spleen and thymus were embedded in paraffin and sliced 4μm,lymphocyte apoptosis index were detected by TUNEL,Bcl-2 and Bax protein expression were detected by immunohistochemistry.The Treg cells were detected by flow cytometry (FCM) in spleen single cell suspension.Explore the possible immune regulation mechanism of Yisui granule on ITP according to detect the factors above-mentioned.
3.Results
3.1 ITP mouse model
GP-APS is still positive when dilution 1:128,indicating guinea pig has generated a specific antibody in serum, that is guinea pig anti-Balb/C mice platelet antibodies. Compared with the normal group,the peripheral blood platelets counts of ITP mouse model decreased significantly,theer was statistically significant (P<0.05,P<0.01).The peripheral platelet counts was lowest after APS injected 24 hours. The counts of megakaryocytes in bone marrow of model group mice increased significantly,but the megakaryocyte which can produce platelet decreased (P< 0.05,P< 0.01).The blood coagulation time of model group was prolonged than normal group (P< 0.001), spleen index of model group was significantly higher than normal group.But the thymus index has no statistically significant as compared with normal group (P< 0.001).
3.2 Experimental study the therapeutic effect of Yisui granuls on ITP mouse model
Compare with model group,the platelet counts of each treatment groups were higher than those of model group,there was statistically significant difference (P<0.01,P<0.001).The counts of platelet in Yisui granules high-dosege group and prednisone group recovered obviously.Compare with model group, immature megakaryocyte proliferation in bone marrow of Yisui granules high-dosage group was inhibited, megakaryocyte which can produce platelet increased,there was statistically significant difference (P<0.01,P< 0.001); The levels of PAIgG of ITP model group were increased significantly than normal group.The levels of PAIgG decreased significantly after treatment with Yisui granules,it was significantly lower than model group (P< 0.001),there was no statistically significant different compared with the normal group.The spleen index of each treatment groups decreased than model group,the Yisui granuls high-dosage group decreased obviously,there was statistically significant difference (P< 0.001)
3.3 Experimental study the immunological network regulation mechanism of Yisui granuls on ITP mouse model
Compared with normal group,the levels of IFN-γincreased in model group,the levels IL-4 decreased in model group,the ratio of IFN-γ/IL-4 increased. The balance between Thl and Th2 was brouken out. ITP has cellular immune function dereased and T cell subsets drift, manifestation of a type-1 polarized immune response.The proportion of Treg cells and the levels of TGF-β1 was significantly lower in model group as compared to normal group. Compared to normal group,spleen lymphocyte apoptosis decreased,Bcl-2 protein expression increased,Bax protein expression decreased in model group.But the thymus lymphocyte apoptosis and Bcl-2,Bax protein expression were no statistically significant difference in each group.After treatment,compared with model group,the levels of IFN-γand the ratio of IFN-γ/IL-4 decreased,the levels of IL-4 increased in YiSui Granules group. The proportion of Treg cells and the levels of TGF-β1 was higher in YiSui granules group as compared to model group.However,the proportion of Treg cells was lower in YiSui granules group than that in normal group, there is no significant difference of the levels of TGF-β1 in YiSui granules group as compared to normal group.Compared to model group,spleen lymphocyte apoptosis increased,Bcl-2 protein expression decreased,Bax protein expression increased in YiSui granules group.
4.Conclusions
4.1 Successfully preparation GP-APS and established ITP mouse models. The peripheral platelet counts decreased in ITP mouse model,and bone marrow megakaryocytes increased and ysmaturity.It's basically consistent with the clinical manifestations of ITP
4.2Yisui granules can increase the peripheral blood platelet counts of ITP mice effectively and stimulate the bone marrow megakaryocytes differentiation to maturation.Its curative effect was equal to prednisone
4.3 ITP has cellular immune function dereased and T cell subsets drift, manifestation of a type-1 (INF-γ) polarized immune response.The morbidity of ITP may be related to Th1/Th2 cell cytokine imbalance, Treg cells and TGF-β1 was reduced, lymphocyte apoptosis and Bcl-2, Bax protein expression abnormality. Yisui granules may be by regulating the Th1/Th2 cell balance and promote Treg cell proliferation and TGF-β1 secretion, and can regulate lymphocyte apoptosis and apoptosis-regulating genes Bcl-2, Bax abnormal expression, thus regulating the immune abnormalities in ITP,reduceing the platelet-associated antibodies, reducing platelet destruction, increased platelet count, promoting bone marrow megakaryocyte differentiation to mature. surface to achieve therapeutic effectreduce the difference between platelet antibody to reduce platelet destruction, increased platelet count, the promotion of bone marrow megakaryocyte differentiation to mature to achieve therapeutic effect.
免疫性血小板减少性紫癜(immune thrombocytopenic purpura, ITP)是一种以血小板减少和皮肤粘膜出血为特征的自身免疫性疾病。其发病与免疫失调关系密切,但导致免疫功能异常的调控因素仍未完全阐明。临床上应用糖皮质激素、脾切除术等治疗可使70%以上病例血小板数量维持在安全范围,但还有约30%病例此方案治疗无效,需进一步采用其它治疗措施来维持血小板数量在安全水平,防止严重出血。应用糖皮质激素和脾脏切除术治疗无效的病例为难治性ITP (refractory immune thrombocytopenic purpura, RITP)。本研究用外源性抗体注入小鼠体内免疫的方法建立ITP小鼠模型,用益髓颗粒进行干预研究,观察ITP小鼠外周血血小板、骨髓巨核细胞、细胞因子、脾脏和胸腺细胞凋亡指数及凋亡基因表达、脾脏调节性T细胞等指标进行研究,试图从免疫网络调控角度阐明“益髓颗粒”治疗ITP效应机制。
2.方法
制备豚鼠抗Balb/C小鼠血抗小板血清,予红细胞吸附后备用。造模前将20只Balb/C小鼠依据外周血血小板数随机分正常组、模型组。模型组按照100μ1／20g剂量向小鼠腹腔内注入1：4稀释的GP-APS,隔日一次,造模两周后,检测外周血小板计数、骨髓巨核细胞数量及形态分类,观察胸腺及脾脏病理学改变,以判定疾病模型是否成功。
ITP疾病动物模型建立成功后,按血小板计数将70只Balb/C小鼠随机分为正常组、模型组、醋酸泼尼松治疗组、升血小板胶囊治疗组、益髓颗粒大、中、小剂量治疗组,于造模第8天开始各组均按0.2m1／10g体重分别予生理盐水及治疗药物灌胃,每日1次,共7天。通过观察造模小鼠外周血小板计数、骨髓巨核细胞数量及形态分类、血小板相关抗体、脏器指数及免疫组织器官病理学变化等指标,评价益髓颗粒治疗效果。
在确定疗效后,我们按上述造模方法建立ITP,用大剂量益髓颗粒为治疗药进行干预,用ELISA检测与免疫密切相关的Th1/Th2细胞因子(IFN-y/IL-4)及TGF-β1, TUNEL法及免疫组化法分别检测脾脏和胸腺细胞凋亡指数及凋亡基因Bcl-2、Bax的表达,用流式细胞仪检测脾脏调节性T细胞等指标进行研究,探讨益髓颗粒治疗ITP可能的免疫调控机制。
3.结果
3.1 ITP小鼠模型的建立
GP-APS稀释倍数为1：128时仍成阳性,说明豚鼠血清中已产生了特异性抗体,即豚鼠抗Balb/C小鼠血小板抗体。与正常组及造模前比较,ITP小鼠模型外周血血小板明显降低,差异显著有统计学意义(P<0.05,P<0.01),注射APS后24小时模型小鼠外周血小板数最低。模型组小鼠骨髓巨核细胞总数明显增加,而产板巨核细胞减少,与正常组比较,差异显著有统计学意义(P<0.05,P<0.01)。模型组凝血时间明显延长,与正常组比较,差异显著有统计学意义(P<0.001)。模型组小鼠脾脏指数明显大于正常组,差异显著有统计学意义(P<0.001),胸腺指数与正常组比较差异不显著无统计学意义。
3.2益髓颗粒对ITP小鼠模型治疗作用的实验研究
与模型组比,各治疗组血小板数均比模型组有所升高,差异显著有统计学意义(P<0.01,P<0.001),以益髓颗粒大剂量组和泼尼松组血小板升高明显。益髓颗粒大剂量组不成熟的骨髓巨核细胞增生受到抑制,产板巨核细胞增多,与模型组比较,有统计学意义(P<0.01,P<0.001)；模型组PAIgG水平明显升高低,与正常组比差异显著有统计学意义(P<0.001),经治疗后,益髓颗粒组PAIgG水平明显低于模型组,与正常组比差异不明显无统计学意义。与模型组比,各治疗组脾脏均有所缩小,脾脏指数降低,差异显著有统计学意义(P<0.001),以益髓颗粒大剂量组效果明显。
3.3益髓颗粒对ITP小鼠免疫网络调控机制的实验研究
与正常组相比,模型组小鼠IFN-y水平明显升高,IL-4水平明显降低,IFN-γ/IL-4比值升高,Th1/Th2细胞间失衡,提示ITP小鼠存在细胞免疫功能低下及T细胞亚群漂移,表现为Thl细胞优势；Treg细胞比例、TGF-β1水平明显降低,脾脏淋巴细胞凋亡减少,Bcl-2蛋白表达增多,Bax蛋白表达减少,各组胸腺淋巴细胞凋亡及Bcl-2、Bax蛋白差异不明显无统计学意义。而经治疗后ITP小鼠血清INF-y水平降低,IL-4水平长高,IFN-y/IL-4比值降低,与模型组比较,益髓颗粒治疗组的IFN-y降低,IL-4升高,IFN-γ/IL-4比值接近正常；Treg细胞比例及TGF-β1水平均有所提高,但Treg仍未达到正常水平,与正常组比仍存在差异,而TGF-β1与正常组比差异不明显无统计学意义；益髓颗粒组脾脏淋巴细胞凋亡增多,Bcl-2蛋白表达减少,Bax蛋白表达增多。
4.结论
4.1成功制备了GP-APS,IPT小鼠疾病模型建立成功,模型小鼠外周血小板下降、骨髓巨核细胞增多并伴成熟障碍,与ITP临床表现基本相符。
4.2益髓颗粒能有效恢复ITP小鼠的血小板计数,并能促进骨髓巨核细胞向成熟方向分化,与醋酸泼尼松疗效相当。
4.3 ITP存在细胞免疫功能低下及T细胞亚群漂移,表现为Thl细胞优势,其发病可能与Th1/Th2细胞间细胞因子失衡,Treg细胞及TGF-β1含量降低,淋巴细胞凋亡及Bcl-2、Bax蛋白表达异常等相关。益髓颗粒可能通过调节Th1/Th2细胞间的平衡,促进Treg细胞增殖及TGF-β1分泌,并能调节脾脏淋巴细胞凋亡及凋亡基因Bcl-2、Bax的异常表达,进而调节ITP免疫异常,降低血小板相关抗体,减少血小板破坏,提高血小板数量,促进骨髓巨核细胞向成熟方向分化而达到治疗效果。
1.Objective
Immune thrombotopenic purpura is an autoimmune (ITP) disorder characterized by a low platelet count and mucocutaneous bleeding.A number of features suggest this destruction is immune-mediated,But the exact mechanism of the immune dysfunction, however, is generally not known. More than 70% patients response to treatment with glucocorticoids and splenectomy,but there are about 30% of refractory patients (refractory immune thrombocytopenic purpura, RITP) are defined as those in whom treatment with standard-dose corticosteroids and splenectomy fails and who further therapy because of unsafe platelet counts or clinical bleeding.In this study,ITP mouse model were made by injected exogenous antibodies intraperitoneally guinea pig-antimouse platelet serum (GP-APS) and treated with YiSui granules.Observe the effect of Yisui granules on ITP mouse peripheral blood platelets,bone marrow megakaryocytes,cytokines,spleen and thymus apoptosis index and the apoptotic gene expression,regulatory T cells in the spleen and other factors.Trying to explore Yisui granules effective mechanism on the regulation of immune network in ITP.
2.Methods
Preparation of guinea pig anti-Balb/C mice anti-platelet serum (GP-APS) and red blood cell adsorption and reserved.Twenty Balb/c mice were randomly divided into normal group,model group according to the counts of Peripheral platelet.ITP mouse model were made by injected intraperitoneally 1:4 guinea pig-antimouse platelet serum (GP-APS) at a dose of 100μl/20g every other day.Detect the peripheral platelet counts,bone marrow megakaryocyte counts and morphology classification,observe the pathological changes in thymus and spleen to after two weeks in order to judge whether the model was successful or not.
After ITP mouse model was verified successful,seventy Balb/C mice were were randomly divided into normal group,model group,Prednisolone acetate group,ShengXue XiaoBan capsule and Yisui granules high,medium and low-dosege groups.The 8th day establishing the model,each group were intragastric administration at a dose of 0.2ml/10g·d-1 volume with normal saline and every treated medicine daily for additional one week respectively.Evaluate the therapeutic effect of YiSui granules according to detecting the peripheral platelet counts,blood coagulation time, bone marrow megakaryocyte counts and morphology classificatio,platelet-associated antibodies,the immune organ index and the pathological changes.
After the therapeutic effect of YiSui granule had been determined,the ITP mouse model were established as the methods above-mentioned and treated with high dosage of YiSui granules.Two weeks latter,The levels of immune closely related to Thl/Th2 cytokines (IFN-y and IL-4) and TGF-β1 in peripheral blood serum were detected by ELISA.The spleen and thymus were embedded in paraffin and sliced 4μm,lymphocyte apoptosis index were detected by TUNEL,Bcl-2 and Bax protein expression were detected by immunohistochemistry.The Treg cells were detected by flow cytometry (FCM) in spleen single cell suspension.Explore the possible immune regulation mechanism of Yisui granule on ITP according to detect the factors above-mentioned.
3.Results
3.1 ITP mouse model
GP-APS is still positive when dilution 1:128,indicating guinea pig has generated a specific antibody in serum, that is guinea pig anti-Balb/C mice platelet antibodies. Compared with the normal group,the peripheral blood platelets counts of ITP mouse model decreased significantly,theer was statistically significant (P<0.05,P<0.01).The peripheral platelet counts was lowest after APS injected 24 hours. The counts of megakaryocytes in bone marrow of model group mice increased significantly,but the megakaryocyte which can produce platelet decreased (P< 0.05,P< 0.01).The blood coagulation time of model group was prolonged than normal group (P< 0.001), spleen index of model group was significantly higher than normal group.But the thymus index has no statistically significant as compared with normal group (P< 0.001).
3.2 Experimental study the therapeutic effect of Yisui granuls on ITP mouse model
Compare with model group,the platelet counts of each treatment groups were higher than those of model group,there was statistically significant difference (P<0.01,P<0.001).The counts of platelet in Yisui granules high-dosege group and prednisone group recovered obviously.Compare with model group, immature megakaryocyte proliferation in bone marrow of Yisui granules high-dosage group was inhibited, megakaryocyte which can produce platelet increased,there was statistically significant difference (P<0.01,P< 0.001); The levels of PAIgG of ITP model group were increased significantly than normal group.The levels of PAIgG decreased significantly after treatment with Yisui granules,it was significantly lower than model group (P< 0.001),there was no statistically significant different compared with the normal group.The spleen index of each treatment groups decreased than model group,the Yisui granuls high-dosage group decreased obviously,there was statistically significant difference (P< 0.001)
3.3 Experimental study the immunological network regulation mechanism of Yisui granuls on ITP mouse model
Compared with normal group,the levels of IFN-γincreased in model group,the levels IL-4 decreased in model group,the ratio of IFN-γ/IL-4 increased. The balance between Thl and Th2 was brouken out. ITP has cellular immune function dereased and T cell subsets drift, manifestation of a type-1 polarized immune response.The proportion of Treg cells and the levels of TGF-β1 was significantly lower in model group as compared to normal group. Compared to normal group,spleen lymphocyte apoptosis decreased,Bcl-2 protein expression increased,Bax protein expression decreased in model group.But the thymus lymphocyte apoptosis and Bcl-2,Bax protein expression were no statistically significant difference in each group.After treatment,compared with model group,the levels of IFN-γand the ratio of IFN-γ/IL-4 decreased,the levels of IL-4 increased in YiSui Granules group. The proportion of Treg cells and the levels of TGF-β1 was higher in YiSui granules group as compared to model group.However,the proportion of Treg cells was lower in YiSui granules group than that in normal group, there is no significant difference of the levels of TGF-β1 in YiSui granules group as compared to normal group.Compared to model group,spleen lymphocyte apoptosis increased,Bcl-2 protein expression decreased,Bax protein expression increased in YiSui granules group.
4.Conclusions
4.1 Successfully preparation GP-APS and established ITP mouse models. The peripheral platelet counts decreased in ITP mouse model,and bone marrow megakaryocytes increased and ysmaturity.It's basically consistent with the clinical manifestations of ITP
4.2Yisui granules can increase the peripheral blood platelet counts of ITP mice effectively and stimulate the bone marrow megakaryocytes differentiation to maturation.Its curative effect was equal to prednisone
4.3 ITP has cellular immune function dereased and T cell subsets drift, manifestation of a type-1 (INF-γ) polarized immune response.The morbidity of ITP may be related to Th1/Th2 cell cytokine imbalance, Treg cells and TGF-β1 was reduced, lymphocyte apoptosis and Bcl-2, Bax protein expression abnormality. Yisui granules may be by regulating the Th1/Th2 cell balance and promote Treg cell proliferation and TGF-β1 secretion, and can regulate lymphocyte apoptosis and apoptosis-regulating genes Bcl-2, Bax abnormal expression, thus regulating the immune abnormalities in ITP,reduceing the platelet-associated antibodies, reducing platelet destruction, increased platelet count, promoting bone marrow megakaryocyte differentiation to mature. surface to achieve therapeutic effectreduce the difference between platelet antibody to reduce platelet destruction, increased platelet count, the promotion of bone marrow megakaryocyte differentiation to mature to achieve therapeutic effect.
引文
[1]Cooper N,Bussel J.The pathogenesis of immune thrombocytopaenic purpura[J].Br J Haematol, 2006,133(4):364-374
[2]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346(13): 995-1008
[3]Cines DB,McMillan R.Pathogenesis of chronic immune thrombocytopenic purpura [J].Curr Opin Hematol,2007,14(5):511-514
[4]Rodeghiero F,Stasi R,Gernsheimer T,et al.Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood,2009,113(11):2386-2393
[5]Provan D,Stasi R,Newland AC,et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood,2010,115(2):168-186
[6]Nugent D,McMillan R,Nichol NL,et al.Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production[J].Bri J Haematol,2009,146: 585-596
[7]Chang M,Nakagawa PA,Williams SA,et al.Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro[J]. Blood,2003, 102(3):887-895
[8]McMillan R,Wang L,Tomer A,et al.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J].Blood,2004,103(4):1364-1369
[9]Zhou B,Zhao H,Yang RC,et al.Multi-dysfunctional pathophysiology in ITP[J].Crit Rev Oncol Hematol,2005,54(2):107-116
[10]Gernsheimer T.Epidemiology and pathophysiology of immune thrombocytopenic purpura [J].Euro J Haematol,2008,80(Suppl 69):3-8
[11]Gernsheimer T.Chronic idiopathic thrombocytopenic purpura:mechanisms of pathogenesis[J]. The Oncologist,2009,14 (1):12-21
[12]Harrington WJ,Minnich V,Hollingsworth JW,et al.Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura[J].J Lab Clin Med,1951,38(1):1-10
[13]Shulman NR,Marder VJ,Weinrach RS.Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura.Physiologic, serologic and isotopic studies[J].Ann N Y Acad Sci,1965,124 (2):499-542
[14]Shulman NR,Weinrach RS,Libre EP,et al.The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura[J].Trails Assoc Am Physicians,1965,78: 374-390
[15]McMillan R, Smith RS,Longmire RL,et al.Immunoglobulins associated with human platelets, [J].Blood,1971,37(3):3163-3122
[16]Dixon R,Rosse W,Ebbert L.Quantitative determination of antibody in idiopathic thrombocyto-penic purpura. Correlation of serum and platelet-bound antibody with clinical response[J].N Engl J Med,1975,292:230-236
[17]McMillan R,Tani P,Millard F,et al. Platelet-associated and plasma anti-glycoprotein autoanti-bodies in chronic ITP[J].Blood,1987,70(4):1040-1045
[18]Kiefel V, Santoso S, Kaufmann E, et al.Autoantibodies against platelet glyco-protein Ib/IX:a frequent finding in autoimmune thrombocytopenic purpura[J].Br J Haematol,1991,79(2):256-262
[19]Woods VL, Oh EH, Mason D,et al. Autoantibodies against the platelet glyco-protein Ⅱb/Ⅲa complex in patients with chronic ITP[J].Blood,1984,63 63(2):368-375
[20]Hou M, Stockelberg D, Kutti J,et al.Antibodies against platelet GPⅠb/Ⅸ, GPⅡb/Ⅲa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol,1995,55 (5):307-314
[21]Brighton TA,Evans S,Castaldi PA,et al.Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias[J].Blood,1996,88(1):194-201
[22]McMillan R.The Pathogenesis of Chronic Immune Thrombocytopenic Purpura[J].Semin Hematol,2007,44(suppl 5):S3-S11
[23]王同保,赵金枝,张欣欣,等.血小板抗体对原发性血小板减少性紫癜巨核细胞成熟发育的影响[J].中华儿科杂志,1995,33(2)：112-113
[24]王萍萍,卢香兰,李霞.血小板相关抗体对原发性血小板减少性紫癜患者巨核细胞数量及成熟程度的影响[J].中国医科大学学报,2003,32(4)：348-350
[25]Houwerzijl EJ,Blom NR,vail der Want JJ,et al.Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thromboeytopenic purpura[J].Blood,2004,103(2):500-506
[26]Stahl CP, Zucker-Franklin D, McDonald TP. Incomplete antigenic cross-reactivity between platelets and megakaryocytes:relevance to ITP[J].Blood,1986,67(2):421-428
[27]Moore PA,Belvedere O,Orr A,et al.BLyS:member of the tumor necrosis factor family and B lymphocyte stimulator[J].Science,1999,285(5425):260-263
[28]Schneider P,MacKay P,Steiner V,et al.BAFF,an novel ligand of the tumor necrosis factor family,stimulates B cell growth[J].J Exp Med,1999,189(11):1747-1756
[29]Schneider P,Tschopp J.BAFF and the regulation of B cell survival[J].Immunol Lett,2003:88 (1):57-62
[30]Emmerich F,Bal QBarakat A,et al.High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura[J].Br J Haematol,2006, 136(2):309-314
[31]Zhou ZP,Chen ZP,Li HQ,et al.BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura[J].Autoimmunity,2009,42(2):112-119
[32]Zhu XJ,Shi Y,Peng J,et al.The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia[J].Blood,2009,114(26):5362-5367
[33]Arfors L,Winiarski J,Lefvert AK.Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes[J].Eur J Haematol,1996,56(4):230-234
[34]Stasi K,Stipa E,Masi M, et al.Prevalence and clinical significance of elevated anti-phos-pholipid antibodies in patients with idiopathic thrombocytopenic purpura[J].Blood,1994,84(12): 4203-4208
[35]Love PE, Santoro SA.Antiphospholipid antibodies:anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders.Prevalence and clinical significance[J].Ann Intern Med,1990,112(9):682-698
[36]李一荣,姜伟超,邢辉,等.慢性特发性血小板减少性紫ANA和ACA的检测及临床意义[J].临床血液学杂志,2003,16(6)：286-287
[37]Galli M,Daldossi M,Barbui T. Anti-glycoprotein Ⅰb/Ⅸ and Ⅱb/Ⅲa antibodies in patients with antiphospholipid antibodies[J].Thromb Haemost,1994,71(5):571-575
[38]van Leeuwen EF,van der Ven JT,Engelfriet CP. Specificity of autoantibodies in auto-immune thrombocytopenia[J].Blood,1982,59(1):23-26
[39]McMillan R.Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura [J].Semin Hematol,2000,37(3):239-248
[40]Escher R,Muller D,Vogel M, et al.Recombinant human natural autoantibodies against GPIlb/ Ⅲa inhibit binding of autoantibodies from patients with AITP[J].Br J Haematol,1998,102 (3):820-828.
[41]Kuwana M,Kaburaki J,Kitasato H,et al.Immunodominant epitopes on glycoprotein Ⅱb/Ⅲa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura[J].Blood, 2001,98(1):130-139
[42]McMilla R,Lopez-Dee J,Bowditch R.Clonal restriction of platelet-associated anti-GP Ⅱb/Ⅲa autoantibodies in patients with chronic ITP[J].Thromb Haemost,2001,85 (5):821-823'
[43]Beardsley DS.ITP in the 21st century.Hematology Am Soc Hematol Educ Program.2006: 402-407
[44]Abbas AK,Murphy KM,Sher A.Functional diversity of helper T lymphocytes[J].Nature,1996, 383(6603):787-793
[45]Semple JW, Freedman J.Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia[J].Blood,1991,78(10):2619-2625
[46]Semple JW, Milev Y, Cosgrave D, et al.Difference in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity[J].Blood,1996,87(10):4245-4254
[47]Kuwana M, Kaburaki J, Ikeda Y.Autoreactive T cells to platelet GPⅡb-Ⅲa in immune thrombocytopenic purpura:role in production of antiplatelet autoantibody[J].J Clin Invest,1998, 102(7):1393-1402
[48]Ware RR,Howard TA.Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura[J].Blood,1993,82(7):2137-2142
[49]Filion MC,Bradley AJ,Devine DV,et al.Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy[J].Eur J Immunol,1995,25(11):3123-3127
[50]Shimomura T, Fujimura K, Takafuta T, et al.Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura[J].B J Haematol.1996,95(4):732-737
[51]Roark JH,Bussel JB,Cines DB,et al.Genetic analysis of autoantibodies in idiopathic thrombo-cytopenic purpura reveals evidence of clonal expansion and somatic mutation[J].Blood,2002, 100(4):1388-1398
[52]Garcia-Suarez J,Prieto A,Reyes E,et al.Abnormal γIFN and aTNF secretion in purified CD2+ cells from autoimmune thrombocytopenic purpura (ATP) patients:Their implication in the clinical course of the disease[J].Am J Hematol,1995,49(4):271-276
[53]Yoshimura C,Nomura S,Nagahama M,et al.Plasmasoluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura[J].Eur J Haematol,2000,64 (4):219-224
[54]Lechler R,Chai JQMarelli-Berg F,et al.The contributions of T-cell anergy to peripheral T-cell tolerance [J].Immunology,2001,103(3):262-269
[55]Koshy M, Berger D,Crow MK.Icreased expression of CD40 ligand on systemic lupus erythematosus lymphocytes[J].J Clin Invest,1996,98(3):826-837
[56]Czapiga M,Kirk AD,Lekstrom-Himes J.Platelets deliver costimulatory signals to antigen-presenting cells:a potential bridge between injury and immune activation[J].Exp Hematol,2004,32 (2):135-139
[57]Henn V,Slup sky JR,Grafe M,et al.CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells[J].Nature,1998,391(6667):591-594
[58]WebberNP, Mascarenhas JO,CrowMK, et al.Functional properties of lymphocytes in idiopathic thrombocytopenic purpura[J].Hum Immunol,2001,62(12):1346-1355
[59]Solanilla A,Pasquet JM,Viallard JF,et al.Platelet-associated CD154 in immune thrombocyto-penic purpura[J].Blood,2005,105(1):215-218
[60]Meabed MH,Taha GM,Mohamed SO,et al.Autoimmune thrombocytopenia:flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes[J].Hematology,2007,12(4):301-307
[61]Nagahama M, Nomura S, Kanazawa S, et al.Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura[J].Eur J Haematol,2002,69(5-6): 303-308
[62]赵艳霞,高清平,陈友华,等.特发性血小板减少性紫癜患者外周血淋巴细胞协同刺激分子的表达[J].中华血液学杂志,2003,24(9)：474-476
[63]Fan Y,Ge Y,Zhu H,et al.Characterization and application of two novel monoclonal antibodies against CD40L:epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L [J].Tissue Antigens,2004,64(3):257-263
[64]Zhang XL, Peng J, Sun JZ,et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura[J].J Thromb Haemost,2008,6(1):158-165
[65]Catani L, Fagioli ME, Tazzari PL, et al.Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes [J].Exp Hematol, 2006,34(7):879-887
[66]Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein Ⅱb/Ⅲa by blockade of CD40/CD154 interaction:implications for treatment of immune thrombocytopenic purpura[J].Blood,2003,101 (2):621-623
[67]Hou M,Peng J,Shi Y, et al.Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura[J].Eur J Haematol,2003,70(6):353-357
[68]Peng J,Liu C,Liu D,et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura [J].Blood,2003,101 (7):2721-2726
[69]Mosmann TR,Sad S.The expanding universe of T-cell subsets:Th1,Th2 and more[J]. Immunol Today.1996,17(3):138-146
[70]Romangnani S.Thl and Th2 in human diseases[J].Clin Immunol Immunopath.1996,80(3 Pt 1): 225-235
[71]Newton C,Klein T,Friedman H.The role of macrophages in THC-induced alteration of t he cytokine network[J].Adv Exp Med Biol,1998,437:207-214
[72]Haggqvist B,Hultman P.Effects of deviating the Th-2 response in murine mercury-induced autoimmunity towards a Thl-response[J].Clin Exp Immunol,2003,134(2):202-209
[73]Mosmann TR,Kobie JJ,Lee FEH,et al.T helper cytokine patterns:defined subsets, random expression, and external modulation[J].Immunol Res.2009,45(2-3):173-184
[74]魏海明,刘志,田志刚,等.检测Thl／Th2亚群的意义[J].中华医学检验杂志.1998,21(1)：56-59
[75]Nakamura T,Lee RK,Nam SY,et al. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype[J].J Immunol,1997,158(6):2648-2653
[76]Maneti R,Parrinchi P,Giudizi M,et al.Natural killer cell stimulatory factor (Interleukin-12 [IL-12]) induces T helper type1(Thl)-specific immune responses and inhibitis the development of IL-4 producing Th cells[J].J Exp Med,1993,177(4):1199-1204
[77]Liblau RS,Singer SM,Mcdevitt HO.Thl and Th2 CD4+T cells in the pathogenesis of organ-specific autoimmune disease[J].Immunol Today.1995,16(1):34-38
[78]Matsuzaki J, Tsuji T, Imazeki I,et al.Immunosteroid as a regulator for Thl/Th2 balance:Its possible[J].Autoimmunity,2005,38(5):369-375
[79]Chanock S.The etiology of childhood immune thrombocytopenic purpura:how complex is it?[J].J Pediatr Hematol Oncol,2003,25(Suppl 1):S7-10
[80]Mouzaki A,Theodoropoulou M,Gianakopoulos I,et al.Expression patterns of Thl and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura(ITP) at presentation and their modulation by intravenous immunoglobulin G(IVIg) treatment:their role in prognosis[J]. Blood,2002,100(5):1774-1779
[81]Panitsas FP,Theodoropoulou M,Kouraklis A,et al.Adult chronic idiopathic thrombocytopenic purpura(ITP) is the manifestation of a type-1 polarized immune response [J].Blood,2004,103 (7):2645-2647
[82]Ogawara H,Handa H,Morita K,et al.High Thl/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol,2003,71(4):283-288
[83]Panitsas FP,Kouraklis A.Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP)[J].BMC Blood Disord,2004,4(1):4
[84]Olsson B,Andersson PO,Jernas M,et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J].Nat Med,2003,9(9):1123-1124
[85]王宁玲,戴海明,祝怀平,等.特发性血小板减少性紫癜患儿Th1/Th2相关细胞因子的检测[J].中华血液学杂志,2002,23(9)：486-487
[86]阮积晨,赵芹,周海霞,等.特发性血小板减少性紫癜患儿Th亚群细胞因子的检测[J].中国小儿血液与肿瘤杂志,2006,11(4)：22-24
[87]杨小猛,刘仿,陈群,等.特发性血小板减少性紫癜患儿Th1/Th2. Tc1/Tc2亚群漂移的研究[J].中国免疫学杂志,2005,21(1)：76-79
[88]Crossley AR,Dickinson AM,Proctor SJ,et al.Effects of interferon-a therapy on immune parameters in immune thrombocytopenic purpura[J].Autoimmunity.1996,24(2):81-100
[89]Lazarus AH,Ellis J,Semple JW,et al. Comparison of platelet immunity in patients with SLE and with ITP[J].Transfus Sci.2000,22(1-2):19-27
[90]王国兵,李成荣,李长钢,等.儿童急性ITPTh1/Th2细胞功能状态初步研究[J].中国小儿血液与肿瘤杂志,2008,13(4)：156-160
[91]谭柏林,赵谢兰,尹楚兰.特发性血小板减少性紫癜患者IL-2受体的变化[J].湖南医科大学学报，1998,23(2)：191-193
[92]Erduran E,Aslan Y,Aliyazicioglu Y,et al.Plasma soluble interleukin-2 receptor levels in patients with idiopathic thrombocytopenic purpura[J].Am J Hematol.1998,57:119-123
[93]Letterio JJ,Roberts AB.Regulation of immune responses by TGF-beta[J].Ann Rev Immunol,1998,16:137-161
[94]Fukaura H, Kent SC, Pietrusewicz MJ,et al.Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients[J].J Clin Invest,1996,98(1):70-77
[95]Bridoux F,Badou A,Saoudi A,et al.Transforming growth factorβ(TGF-β)-dependent inhibition of T helper cell 2(Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class Ⅱ-specific,regulatory CD4+T cell lines[J].J Exp Med,1997,185(10):1769-1775
[96]Chen Y, Kuchroo VK,Inobe J,et al.Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis[J].Science,1994,265(5176):1237-1240
[97]Cross D,Cambier JC.Transforming growth factor betal has differential effects on B cell proliferation and activation antigen expression[J].J Immunol,1990,144(2):432-439
[98]Gorelik L.Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease[J].Immunity,2000,12(2):171-181
[99]Sakamaki S,Hirayama Y,Matsunaga T,et al.Transforming growth factor-β1 (TGF-β1) induces thrombopoietin from bone marrow stromal cells,which stimulates the expression of TGF-β receptor on megakaryocytes and,in turn,renders them susceptible to suppression by TGF-β itself with high specificity[J].Blood,1999,94(6):1961-1970
[100]鞠秀丽,丁红芳,魏伟,等.血小板生成素和转化生长因子-β1与儿童特发性血小板减少性紫癜的相关性研究[J].中国实用儿科杂志,2004,19(11)：663-665
[101]Andersson PO,Stockelberg D,Jacobsson S,et al.A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura[J].Ann Hematol,2000,79(9):507-513
[102]Fahim NM, Monir E.Functional role of CD4+CD25+regulatory T cells and transforming growth factor-betal in childhood immune thrombocytopenic purpura[J].Egypt J Immunol.2006, 13(1):173-187
[103]Boshkov LK,Kelton JQHalloran PF. HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura[J].Br J Haematol,1992,81(4):552-557
[104]Semple JW,Mitelman B,Allen D,et al. Platelet HLA-DR expression is mediated by physical interaction with adherent CD 14+macrophages:Possible role in the pathogenesis of autoimmune thrombocytopenia[J].Blood,1995,86:2148(suppl,abstr)
[105]王林,张峰,朱媛媛,等.特发性血小板减少性紫癜患者自身血小板的细胞毒杀伤机制[J].中华医学杂志,2005,85(43)：3048-2053
[106]Adams JM,Cory S.The Bcl-2 protein family:Abiters of cell survival[J].Science,1998, 281(5381):1322-1326
[107]Petros AM,Olejniczak ET,Fesik SW.Structural biology of the Bcl-2 family of proteins[J]. Biochim Biophys Acta,2004,1644(2-3):83-94
[108]Cosulich SQWorrall V,Hedge PJ,et al.Regulation of apoptosis by BH3 domains in a cell-free system[J].Curre Biol,1997,71(12):913-920
[109]Breckenridge DQXue D.Regulation of mitochondrial membrane permeabilization by Bcl-2 family proteins and caspases[J].Curr Opin Cell Biol,2004,16(6):647-652
[110]Sharpe JC,Arnoult D,Youle RL.Crontrol of mitochondrial permeability by Bcl-2 family members[J].Biochim Bionhys Acta,2004,1644(2-3):107-113
[111]Rosse T,Olivier R,Monney L,et al.Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c[J].Nature.1998,391(6666):496-499
[112]周桔,罗荣保,汤长发,等.Bcl-2蛋白家族和p53基因在细胞凋亡中的调控效应[J].中国组织工程研究与临床康复,2007,11(10)：1950-1952
[113]Kuwana,Newmeyer.Bcl-2 family proteins and the role of mitochondria in apoptosis[J].Curr Opin Cell Biol,2003,15(4):691-699
[114]Lalier L,Cartron PFJuin P,et al.Bax activation and mitochondrial insertion during apoptosis [J].Apoptosis.2007,12(5):887-896
[115]Korsmeyr SJ.Bcl-2 gene family and the regulation of programmed cell death [J].Cancer Res.1999,59(7Suppl):1693-1700
[116]Eguchi K.Apoptosis in autommune diseases[J].Inter Med.2001,40(4):275-284
[117]Olsson B,Andersson PO, Jacobsson S,et al.Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura[J].Thromb Haemost,2005,93(1):139-144
[118]王琼玉,高清平.细胞凋亡和增殖在特发性血小板减少性紫癜中的作用[J].临床内科杂志,2003,20(8)：421-423
[119]孟瑞锋,盛光耀,王利.淋巴细胞凋亡异常在AITP患儿中的作用研究[J].医药论坛杂志,2006,27(14)：37-38转41
[120]张静,凌云,曹祥山,等.特发性血小板减少性紫癜患者CD3+、CD4+和CD8+T淋巴细胞凋亡率的研究[J].临床血液学杂志,2009,22(9)：460-462
[121]Moulian N,Renvoize C,Desodt C,et al.Function Fas expression in human themic epithelial cells[J].Blood,1999,93(8):2660-2670
[122]Ju ST,Pomka DJ,Cui H,et al.Fas(CD95)/FasL interaction reguired for programmed cell death T-cell activation[J].Nature,1995,373(6513):444-450
[123]高清平,黄望香,李秀珍.慢性特发性血小板减少性紫癜淋巴细胞和血小板凋亡蛋白的表达[J].临床内科杂志,2001,14(3)：104-106
[124]刘仿,肖红,孟琼,等.特发性血小板减少性紫癜淋巴细胞凋亡及凋亡蛋白表达的研究[J].中国免疫学杂志,2004,20(3)：46-49
[125]Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol.1995,155 (3):1151-1164
[126]Bluestone JA, Abbas AK.Natural versus adaptive regulatory T cells[J].Nat Rev Immunol, 2003,3(3):253-257
[127]Shevach EM.CD4+CD25+Suppressor T cells:more questions than answers[J].Nat Rev Immunol,2002,2(6):389-400
[128]Piccirillo CA,Thornton AM.Cornerstone of peripheral tolerance:naturally occurring CD4+ CD25+regulatory T cells[J].Trends Immunol,2004,25(7):374-380
[129]Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4[J].J Exp Med,2000,192(2):303-310
[130]Lan RY,Ansari AA,Lian ZX,et al.Regulatory T cells:development,function and role in autoimmunity[J].AutoimmuRev,2005,4(6):351-363
[131]Hori S, Nomura T, Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science,2003,299(5609):1057-1061
[132]Fontenot JD,Gavin MA,Rudensky AY.Foxp3 programs the development and function of CD4+CD25+regulatory T cells[J].Nat Immunol,2003,4(4):330-336
[133]Shevach EM.Certified professionals:CD4+CD25+suppressor T cells[J].J Exp Med.2001, 193(11):F41-45
[134]Thompson C,Powrie F.Regulatory T cells[J].Curr Opin Pharmacol.2004,4(4):408-414
[135]Sakaguchi S,Yamaguchi T,Nomura T,et al.Regulatory T Cell and Immune Tolerance[J]. Cell. 2008,133(5):775-787
[136]Taams LS,van Amelsfort JM.Tiemessen MM,et al.Modulation of monocytemacrophage function by human CD4+CD25+regulatory T cells[J].Hum Immunol,2005,66(3):222-230
[137]Chatila TA.Role of regulatory T cells in human diseases[J].J Allergy Clin Immunol. 2005,116(5):949-959
[138]Sakaguchi S.Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses[J].Allnu Rev Immunol,2004,22:531-562
[139]Horwitz DA,Zheng SG,Gray JD.The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+CD25+and CD8+regulatory T cells subsets[J].J Leukoc Biol,2003,74(4):471-478
[140]Cederbom L,Hall H,Ivars F.CD4+CD25+regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells[J].Eur J Immunol,2000,30(6):1538-1543
[141]Kursar M,Bonhagen K,Fensterle J,et al.Regulatory CD4+CD25+ T cells restrict memory CD8+T cell responses[J].J Exp Med,2002,196(12):1585-1592
[142]Azuma T,Takahashi T,Kunisato A,et al.Human CD4+CD25+regulatory T cells suppess NKT cell function[J].Cancer Res,2003,63(15):4516-4520
[143]Lim HW,Hillsamer P,Banham AH,et al.Cutting Edge:Direct Suppression of B Cells by CD4+CD25+Regulatory T Cells[J].J Immunol,2005,175(7):4180-4183
[144]Zhao DM,Thornton AM,Dipaolo RJ,et al.Activated CD4+CD25+T cells selectively kill B lymphocytes[J].Blood,2006,107(10):3925-3932
[145]Hsu WT,Suen JL,Chiang BL.The role of CD4+ D25+ T cells in autoantibody production in murine lupus[J].Clin Exp Immunol,2006,145(3):513-519
[146]何伟刚,曹雪涛.CD4+CD25+调节性T细胞与负向免疫调控及免疫耐受[J].国际肿瘤学杂志,2006,33(5)：324-328
[147]Boehmer H.Mechanisms of suppression by suppressor T cells[J].Nat Immunol,2005,6(4): 338-44
[148]Nakamura K,Kitani A,Strober W.Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β[J].J Exp Med.2001,194(5):629-644
[149]Nakamura K,Kitani A,Fuss I,et al.TGF-β1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice[J].J Immunol.2004,172(2):834-842
[150]Yamagiwa S,Gray JD,Hashimoto S,et al.A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory cells from human peripheral blood[J].J Immunol.2001,166(12):7282-7289
[151]Pyzik M,Piccirillo CA.TGF-betal modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets[J].J Leukoc Biol,2007,82(2):335-346
[152]Strauss L,Bergmann C,Szczepanski M,et al.A unique subset of CD4+CD25 high Foxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment[J].Clin Cancer Res,2007,13(15):4345-4354
[153]Zhang L,Yi H,Xia XP,et al.Transforming growth factor-beta:an important role in CD4+ CD25+ regulatory T cells and immune tolerance[J].Autoimmunity,2006,39(4):269-276
[154]Kawahata K,Misaki Y,Yamauchi M,et al.Generation of CD4+CD25+regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression[J].J Immunol.2002,168 (9):4399-4405
[155]Pacholczyk R,Kraj P,Lgnatowicz L.Peptide specificity of thymic selection of CD4+CD25+T cells[J].J Immunol.2002,168(2):613-620
[156]Sidorenko SP,Clark EA.The dual-function CD 150 receptor subfamily:the viral at reaction[J]. Nat Immunol.2003,4(1):19-24
[157]Okazaki T,Maeda A,Nishimura H,et al.PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine[J].Proc Natl Acad Sci USA,2001,98(24):13866-13871
[158]Balandina A,Lecart S,Dartevelle P,et al.Functional defect of regulatory CD4+CD25+T cells in the thymus of patients with autoimmune myasthenia gravis[J].Blood.2005,105(2):735-741
[159]Lin SC,Chen KH,Lin CH,et al.The quantitative analysis of peripheral blood Foxp3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients[J].Eur J Clin Invest,2007,37(12):987-996
[160]Jiao Z,Wang WJia R,et al.Accumulation of FoxP3-expressing CD4+CD25+T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis[J].Scand J Rheumatol.2007,36(6):428-433
[161]Sakakura M,Wada H,Tawara I,et al.Reduced CD4+CD25+T cells in patients with idiopathic thrombocytopenic purpura[J].Thromb Res.2007,120(2):187-193
[162]Liu B,Zhao H,Poon MC,et al.Abnormality of CD4+CD25+regulatory T cells in idiopathic thrombocytopenic purpura[J].Eur J Haematol.2007,78(2):139-143
[163]Yu J,Heck S,Patel V,et al.Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura[J].Blood,2008,112(4):1325-1328
[164]赵湜,王红祥,李菁缓,等.调节性T细胞在慢性特发性血小板减少性紫癜中的作用[J].中华血液学杂志,2006,27(3)：203-205
[165]伍昌林,党鑫堂,薛俭成.CD4+CD25+调节性T细胞在ITP患者发病机制中的作用[J].临床输血与检验,2008,10(4)：297-300
[166]舒汨汨,曹星梅,张王刚.CD4+CD25 high T细胞在特发性血小板减少性紫癜发病机制中的作用[J].中国实验血液学杂志,2008,16(4)：875-877
[167]张爱梅,徐修才,王宁玲,等.CD4+CD25+Treg在儿童急性免疫性血小板减少性紫癜发病机制中的作用[J].临床儿科杂志,2009,27(12)：1157-1161
[1]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346 (13): 995-008
[2]陈信义,麻柔,李冬云.规范常见血液病中医病名建议[J].中国中西医结合杂志,2009,29(11)：1040-1041
[3]李宜中.中西医结合治疗急性原发性血小板减少性紫癜的体会[J].天津中医药,1992,(1)：16-17
[4]古学奎,李文晞,胡莉文.丘和明教授治疗特发性血小板减少性紫癜经验介绍[J].新中医,2005,37(10)：7-9
[5]那丽,雍延礼,刘丽梅,等.孙伟正教授治疗原发性血小板减少性紫癜经验[J].中医药信息,2008,25(4)：47～48
[6]周永明,程军.原发性血小板减少性紫癜的病机特点和治疗对策[J].辽宁中医杂志,2001,28(12)：714～715
[7]吴晓勇.傅汝林治疗治疗特发性血小板减少性紫癜经验拾萃[J].辽宁中医杂志,2008,35(11)：1634-1635
[8]曾英坚,于天启,陈志雄.陈志雄教授运用祛风法治疗特发性血小板减少性紫癜经验[J].辽宁中医药大学学报,2008,10(11)：86-87
[9]李芮.焦中华治疗原发性血小板减少性紫癜经验[J].中医杂志,2006,47(8)：579-580
[10]许毅,黄振翘.黄振翘教授调补泻火法治疗难治性特发性血小板减少性紫疲经验介绍[J].新中医,2005,37(9)：12-13
[11]田胜利,姚乃中.姚乃中运用温肾填精、凉血活血法治疗特发性血小板减少性紫癜经验[J].上海中医药杂志,2007,41(6)：12-13
[12]李海燕,陶淑春.陶淑春治疗原发性血小板减少性紫癜的经验[J].辽宁中医杂志,2003,30(1)：16-17
[13]裴明创,王兴丽,阮文让,等.戴锡孟教授治疗原发性血小板减少性紫癜经验[J].天津中医药,2007,24(1)：79-80
[14]周永明,周韶红,黄振翘,等.泻火宁血健脾滋肾法治疗难治性原发性血小板减少性紫癜35例[J].上海中医药杂志,2002,(1)：22-23
[15]袁乃荣,魏学礼,周永明.谈中医治疗特发性血小板减少性紫癜要旨[J].辽宁中医学院学报,2005,7(2)：105-106
[16]傅汝林,刘宏潇,张雅丽.归脾汤加减治疗特发性血小板减少性紫癜68例分析[J].中医药学刊,2002,20(1)：26-27
[17]孙士玲,王祥麒,党辉,等.中药治疗特发性血小板减少性紫癜临床研究[J].辽宁中医杂志,2009,36(1)：73-75
[18]闰桂荣,李岳勃,刘子华.辨证治疗原发性血小板减少性紫癜64例[J].实用中医内科杂 志,2001,15(2)：31-32
[19]潘铭.辨证治疗血小板减少性紫癜123例分析[J].甘肃中医,2001,14(6)：31-32
[20]张艳玲.辩证治疗原发性血小板减少性紫癜[J].华厦医学,2002,15(3)：395-396
[21]叶明.辨证治疗慢性原发性血小板减少性紫癜32例疗效观察[J].北京中医杂志,2002,21(3)：141-142
[22]王丽,柯微君,王玉明,等.免疫性血小板减少性紫癜慢性型88例的分型与治疗[J].北京中医,2003,22(4)：9-1 1
[23]吴秀毅.辩证治疗血小板减少性紫癜[J].实用中医内科杂志,2000,14(3)：36
[24]张金先,王金廷,刘建文.特发性血小板减少性紫癜中医证治法则[J].辽宁中医杂志,2000,27(11)：502
[25]李文梅,赵保丽.活血化瘀法治疗原发性血小板减少性紫癜[J].黑龙江中医药,2000,(1)：10-11
[26]程志,吴艺,陈疏敏,等.中西医结合治疗儿童慢性血小板减少性紫癜36例[J].中医研究,2005,18(10)：45-46
[27]杨文华,高宏,王兴丽.中西医结合治疗慢性特发性血小板减少性紫癜80例[J].辽宁中医杂志,2007,34(8)：1044-1045
[28]陈世明,汪玉芳,刘有平.中西药治疗特发性血小板减少性紫癜85例疗效观察[J].时珍国医国药,2006,17(6)：1056-1057
[29]王龙,向永胜,中西医结合治疗慢性特发性血小板减少性紫癜60例[J].内科,2009,4(6)：881-882
[30]丁丽,吴子茂.中西医结合治疗小儿特发性型血小板减少性紫癜[J].深圳中西医结合杂志,2009,19(5)：295-297
[31]杨宏光,陈志雄,于天启.中西医结合治疗特发性血小板减少性紫癜激素抵抗28例[J].山东中医药大学学报,2007,31(6)：481-482
[32]陈健一,李晓惠,张永健,等,补肾凉血解毒法配合激素治疗特发性血小板减少性紫癜36例[J].四川中医,2006,24(12)：56-57
[33]周红,王沁.中西医祛合治疗小儿原成性血小板减少性紫癜63例疗效观察[J].新中医,2005,37(10)：57-58
[34]罗耀光,刘燕群,胡俊,等.重组炙甘草汤配合小剂量糖皮质激素治疗特发性血小板减少性紫癜的临床观察[J].中国中西医结合杂志,2001,21(7)：501-503
[35]陈育生.环孢菌素A合中药治疗难治性特发性血小板减少性紫癜12例[J].现代中西医结合杂志,2003,12(9)：923-924
[36]周永明,胡明辉,杨镜明,等.生血灵治疗特发性血小板减少性紫癜的临床研究[J].中西医结合学报,2004,2(6)：421-425
[37]甘欣锦,李晓惠,张文曦,等.血可宁治疗特发性血小板减少性紫癜临床观察[J].南京中医药大学学报,2007,23(5)：287-288
[38]刘敏,宋明福,赵为军,等.“生血二号”治疗慢性特发性血小板减少性紫癜36例临床研究[J].四川中医,2008,26(11)：65-66
[39]胡凯文,储真真,陈信义,等.健脾活血方治疗难治性慢性型血小板减少性紫癜的临床观察[J].中国医药学报,2002,17(5)：286-288
[40]郭春兰,孙风.紫茜胶囊治疗特发性血小板减少紫癜120例临床观察[J].黑龙江中医药,2008,(3)：9-10
[41]彭素娟,蒋文明.牛角地黄冲剂治疗慢性难治性特发性血小板减少性紫癜40例总结[J].湖南中医杂志,2007,23(1)：28-29
[42]张永锋,刘立昌,夏洪生.归蓉补血片治疗特发性血小板减少性紫癜2例[J].安徽中医学院学报,2003,22(1)：18-20
[43]代喜平,李达,梁冰.紫癜灵治疗慢性难治性特发性血小板减少性紫癜28例[J].吉林中医药,2005,35(3)：21-23
[44]刘凌,冯莹,庞缨,等.升血小板胶囊治疗特发性血小板减少性紫癜的疗效观察[J].中国医院用药评价与分析,2004,4(4)：233-235
[45]王炜.升血小板胶囊联合强的松治疗特发性血小板减少性紫癜疗效观察[J].浙江中医杂志,2008,43(11)：641-642
[46]于天启,戴微,杨宏光,等.升血小板胶囊为主综合治疗难治性血小板减少性紫癜15例疗效观察[J].新中医,2007,39(3)：31-32
[47]穆迪嘉.益气补血片治疗原发性血小板减少性紫癜的研究[J].中国社区医师(综合版),2007,9(11)：74
[48]罗玲,黄望香.益气补血片联合强的松治疗特发性血小板减少性紫癜的疗效观察[J].现代医药卫生,2007,23(14)：2064-2065
[49]陈世伦,戴红.金薯叶止血合剂(旋甘口服液)用于特发性血小板减少性紫康的疗效观察.第八届全国中西医结合血液病学术会议.中国湖北武汉.2007.第八届全国中西医结合血液病学术会议论文集.194-195
[50]李琦,吴超.血复康治疗原发性血小板减少性紫癜的临床观察[J].浙江中西医结合杂志,2001,11(6)：343-345
[51]诸孟娟.复方皂矾丸联合泼尼松治疗特发性血小板减少性紫癜30例临床观察[J].河北中医,2009,31(12)：1868-1869
[52]杨宇飞,周霭祥,麻柔,等.免疫性血小板减少性紫癜免疫学改变和中医证候分型的关系[J].中国中西医结合杂志,1992,12(5)：263-266
[53]杨宇飞,周霭祥,麻柔.慢性特发性血小板减少性紫癜免疫学改变和中医辨证分型与预后关系初步分析[J].中国中西医结合杂志,1995,17(7)：401-404
[54]杨宇飞,周霭祥,麻柔.养血清癜汤治疗慢性特发性血小板减少性紫癜临床研究[J].中国中西医结合杂志,1999,19(1)：29-33
[55]辛随成,蒋海平,王乙忠.原发性血小板减少性紫癜中医证型与骨髓巨核细胞数量及DNA 值的关系[J].中医杂志,1995,36(2)：101-102
[56]庄海峰,沈建平.特发性血小板减少性紫癜血小板计数巨核细胞计数及形态学分类与中医证候分型的关系[J].中华中医药学刊,2007,25(8)：1681-1684
[57]陈均法,庄海峰.特发性血小板减少性紫癜免疫学改变与中医症候分型的关系[J].中医药学刊,2006,24(5)：890-891
[58]刘静霞,吕瑞民,向莉.清热凉血、益气活血中药治疗原发性血小板减少性紫癜的实验研究[J].中国中医药科技,1997,4(1)：26转60
[59]朱文伟,周永明,薛志忠,等.慢性ITP外周血单个核细胞Thl/Th2亚群反应状态及生血灵干预研究[J].现代中西医结合杂志,2008,17(33)：5120-5121
[60]朱文伟，周永明,袁乃荣,等.特发性血小板减少性紫癜患者GR亚型的表达及生血灵干预研究[J].上海中医药杂志,2010,44(2)：43-45
[61]俞亚琴,孙伟正,孙风,等.补肾化瘀解毒法治疗特发性血小板减少性紫癜的临床研究[J].安徽中医学院学报,2003,22(1)：16-18
[62]俞亚琴,孙伟正,孙风.补肾化瘀解毒法对ITP患者血浆蛋白C和P-选择素的影响.附：60例病例报告[J].成都中医药大学学报,2003,25(1)：13-15
[63]俞亚琴,孙伟正,孙风.补肾化瘀解毒方药对ITP患者血浆β-血小板球蛋白和血小板第4因子影响的研究[J].云南中医学院学报,2003,26(4)：23-24转28
[64]肖咏,冯晶,廖秋源,等,补肾活血方对ITP患儿P-选择素表达的影响及临床疗效观察[J].中医儿科杂志,2008,4(3)：31-33
[65]孙凤,朱云丽.紫茜胶囊对慢性原发性血小板减少性紫癜患者IL-2、sIL-2R的影响[J].中医药信息,2007,24(2)：62-63
[66]刘葛,孙凤.紫茜胶囊对慢性原发性血小板减少性紫癜患者IL-6的影响[J].中医药信息2006,23(6)：48-49
[67]张宇,孙伟正,孙凤.紫茜胶囊对CITP患者骨髓巨核细胞及IL-4的影响关[J].中医药信息,2007,24(4)：62-63
[68]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志,1994,15(3)：160-161
[69]蒋文明,邓常青,陈大舜,等.大鼠免疫性血小板减少模型的研究[J].中国实验动物学报,1996,4(2)：104-108
[70]薛志忠,周永明,方永华,等.免疫性血小板减少家兔模型的实验研究[J].实验血液学杂志,1995,3(3)：334-336
[71]刘宏潇,张雅丽,田维毅.特发性血小板减少性紫癜脾不统血证动物模型建立[J].辽宁中医杂志,2002,29(9)：571-572
[72]杨宇飞,许勇钢,周霭祥,等.免疫性血小板减少性紫癜病证结合肾阴虚动物模型的建立[J].中国中西医结合杂志,1998,18(6)：191-194
[73]蒋文明,陈大舜,邓常青,等.地黄止血冲剂抗大鼠免疫性血小板减少的作用研究[J].中国中 医基础医学杂志,1998,4(9)：30-33
[74]蒋文明,邱赛红,程纬民,等.牛角地黄冲剂对大鼠免疫性血小板减少模型T细胞亚群的影响[J].中国中医基础医学杂志,2002,8(8)：20-21
[75]蒋文明,邱赛红,胡志光,等.牛角地黄冲剂对免疫性血小板减少大鼠血浆血栓素A2、前列环素I2影响的实验研究[J].中国中医药科技,2003,10(5)：271-272
[76]傅汝林,刘为民,张雅丽,等.归脾冲剂对免疫性血小板减少性紫癜动物模型实验研究[J].中医药学刊,2001,19(4)：312-313
[77]马骥,陶淑春,范颖.一种治疗免疫性血小板减少性紫癜的中药及其生产方法[P].中国专利：200610135073.7,2007-08-15
[78]王缨,夏卫军.加味小柴胡颗粒及其组方对ITP模型小鼠造血系统的影响[J].中华中医药学刊,2008,26(1)：106-108
[79]王缨,夏卫军.加味小柴胡颗粒及其组方对ITP模型小鼠免疫功能的影响[J].中国免疫学杂志,2008,24(2)：131-134
[80]王缨,夏卫军.加味小柴胡颗粒对免疫性血小板减少性紫癜下丘脑-垂体-肾上腺系统的影响[J].北京中医药大学学报,2008,31(8)：553-556
[81]王缨,夏卫军.原发性血小板减少性紫癜模型小鼠血浆内皮素水平与加味小柴胡颗粒及其组方的干预[J].中国组织工程与临床康复,2007,11(33)：6597-6599
[82]孙凤,韩晶,郭春兰,等.紫茜胶囊对原发性血小板减少性紫癜鼠外周血的影响研究[J].中医药信息,2006,23(1)：61-62
[83]王景,郭春兰,孙凤.紫茜胶囊对ITP模型小鼠外周血血小板相关抗体的影响[J].中医药信息,2006,23(5)：70-72
[84]郭春兰,孙凤,王景.紫茜胶囊对ITP模型小鼠外周血细胞因子IL-2及其受体的影响[J].中医药信息,2008,23(5)：58-59
[85]徐平声,李新可,潘善庆,等.西蒙胶囊对兔与大鼠免疫性血小板减少的保护作用[J].中南药学,2006,4(6)：418-450
[86]李健哲,徐平声,李元建.西蒙醇提取物对家兔特发性血小板减少性紫癜白细胞介素-4和干扰素-γ的影响[J].中南药学,2009,7(1)：2-4
[1]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346(13): 995-008
[2]Arnott J,Horsewood P,Kelton JGMeasurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia[J].Blood,1987,69(5):1294-1299
[3]Stenberg PE,Levin J,Corash L.Sustained thrombocytopenia in mice:serial studies of mega-karyocytes and platelets[J].Exp Hematol.1990,18(2):124-132
[4]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志,1994,15(3)：160-161
[5]Alves-Rosa F,Stanganelli C,Cabrera J,et al.Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model[J].Blood,2000,96(8):2834-2840
[6]朱立平,陈学清.免疫学常用实验方法[M].北京：人民军医出版社,2000.1-2,15-22,352-355
[7]富琦,范颖,王家辉,等.免疫性血小板减少性紫癜病证结合动物模型建立与评价[J].中国中医基础医学杂志.2004,10(2)：30-32
[8]Wei H,Ding X,Ren J,et al.A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen[J].J Genet Genomics.2008,35(11):665-671
[9]Iki S,Urabe A.Refractory idiopathic thrombocytopenic purpura[J].Nippon Rinsho.2003,61(4): 609-614
[10]Cines DB, Bussel JB, McMillan RB,et al.Congenital and acquired thrombocytopenia[J]. Hematology(Am Soc Hematol Educ Program).2004:390-406
[11]McKenzie SE,Reilly MP.Heparin-induced thrombocytopenia and other immune thrombocyto-penias:lessons from mousemodels[J].Semin ThrombHemost,2004,30(5):559-568
[12]Meade CJ,Heuer H,Kempe R.Biochemical pharmacology of platelet activating factor(and PAF antagonists) in relation to clinical and experimental thrombocytopenia[J].Biochem Pharmacol, 1991,41 (5):657-668
[13]Kuter DJ,Rosenberg RD.The reciprocal relationship of thrombopoietin(c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit [J].Blood, 1995,85(10):2720-2730
[14]Ashida SI, Abiko Y.Protective effect of pantethine on experimental thrombocytopenia in the rat[J].Thromb Diath Haemorrh,1975,33 (3):528-539
[15]Oyaizu N,Yasumizu R,Miyama-Inaba M,et al.(NZW x BXSB) F1 mouse.A new animal model of idiopathic thrombocytopenic purpura[J].J Exp Med,1988,167(6):2017-2022
[16]Hosono M,Sone N,Endo K,et al.Kinetics of platelets in dogs with thrombocytopenia induced by antiglycoprotein Ilb/IIIa receptor monoclonal antibody[J].Nucl Med Biol,1995; 22 (1):71-76
[17]Coetzee LM,Pieters H,van Wyk V,et al.The effect of monoclonal anti-human-platelet anti-bodies on platelet kinetics in a baboon model:IgG subclass dependency[J].Thromb Haemost,2000, 83(1):148-156
[18]Nieswandt B,Bergmeier W,Rackebrandt K,et al.Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice [J].Blood,2000; 96(7):2520-2527
[19]Harrington WJ,Minnich V,Hollingseorth JW,et al.Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura[J]. J Lab Clin Med,1951,38:1-10
[20]Bentfeld ME,Bainton DF.Cytochemical localization of lysosomal enzymes in rat megakaryo-cytes and platelets[J].J Clin Invest.1975,56(6):1635-1649
[21]Mizutani H,Engelman RW,Kurata Y,et al.Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW X BXSB)F1m ice[J].Blood,1993,82(3):837-844
[22]Crow AR,Song S,Freedman J,et al.IVIg mediated amelioration of murine ITP via FcR ⅡB is independent of SHIP 1,SHP-1,and Btk activity[J].Blood,2003,102:558-560
[23]Karassa FB, Trikalinos TA, Ioannidis JP. The role of Fc γRⅡA and Ⅲ A polymorphisms in autoimmune diseases[J].Biomed Pharmacother,2004,58:286-291
[24]McKenzie SE, Taylor SM, M alladi P, et al.The role of the human Fc receptor/Fc γ RⅡA in the immune clearance of platelets:a transgenic mouse model[J]J Immunol,1999,162:4311-4318
[25]McKenzie SE.Humanized mouse models of FcR clearance in immune platelet disorders [J].Blood Rev,2002,16:3-5
[26]Mason 1, Carpinelli MR, Fletcher JL, et al.Programmed anuclear cell death delimits platelet life span[J].Cell,2007,128(6):1173-1186
[27]Liu Z,Gurlo T,von Grafenstein H.Cell-ELISA using beta-galactosidase conjugated antibodies [J].J Immunol Methods,2000,234(1-2):153-167
[28]Salih AM,Nixon NB,Dawes PT,et al.Antibodies to neuroblastoma cells in rheumatoid arthritis: a potential marker for neuropathy[J].Clin Exp Rheumatol,2000,18(1):23-30
[29]Lee JC,Cevallos AM, NaeemA,et al.Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells[J].Gut,1999,44(2):196-202
[1]Arnott J, Horsewood P, Kelton JGMeasurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia[J].Blood,1987,69(5):1294-1299
[2]Stenberg PE,Levin J,Corash L.Sustained thrombocytopenia in mice:serial studies of mega-karyocytes and platelets[J].Exp Hematol.1990,18(2):124-132
[3]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志.1994,15(3)：160-161
[4]Alves-Rosa F,Stanganelli C,Cabrera J,et al.Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model[J].Blood,2000,96(8):2834-2840
[5]富琦,范颖,王家辉,等.免疫性血小板减少性紫癜病证结合动物模型建立与评价[J].中国中医基础医学杂志.2004,10(2)：30-32
[6]Wei H,Ding X,Ren J,et al.A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen[J]J Genet Genomics.2008,35(11):665-671
[7]许亚梅,姜苗,陈信义.益髓颗粒剂在现代难治血液病中的应用[J].中国医药学报,2004,19(4)：245-246
[8]李冬云,马薇,荣秀梅,等.益髓颗粒组方分析及应用研究[J].中外医疗,2009,(8)：153-154
[9]van Leeuwen EF,van der Ven JT,Engeffriet CP,et al.Specificity of autoantibodies in auto-immune thrombocytopenia[J].Blood,1982,59(l):23-26
[10]McMillan R.Autoantibodies and autoantigens in chronic immune thrombocytopenia purpura [J].Semin Hematol.2000,37:239-248
[11]Fujisawa K,Tani P, OToole TE,et al.Different specificities of platelet-associated and plasma autoantibodies to platelet GPIIb-IIIa in patients with chronic immune thrombocytopenic purpura[J].Blood,1992,79(6):1441-1446
[12]Kiefel V,Santoso S,Kaufmann E,et al.Autoantibodies against platelet glycoprotein Ib/IX:a frequent finding in autoimmune thrombocytopenic purpura[J].Br J Haematol.1991,79(2):256-262
[13]Hou M,Stockelberg D,Kutti J,et al.Antibodies against platelet GPⅠb/IX,GPⅡb/Ⅲa,and other platelet antigens in chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol.1995,55(5): 307-314
[14]Kiefel V, Freitag E, Kroll H, et al.Platelet autoantibodies (IgQ IgM, IgA) against glyco-proteins Ⅱb/Ⅲa and Ⅰb/Ⅸ in patients with thrombocytopenia[J].Ann Hematol.1996,72(4):280-285
[15]Saleh MN,Moore DL,Lee JY,et al. Monocyte-platelet interaction in immune and non-immune thrombocytopenia[J].Blood,1989,74(4):1328-1331
[16]Semple JW.Immune pathophysiology of autoimmune thrombocytopenic purpura[J].Blood rev, 2002,16(1):9-12
[17]McMillan R.The Pathogenesis of Chronic Immune Thrombocytopenic Purpura[J]. Semin Hematol,2007,44(Suppl 5):S3-S11
[18]Chang M,Nakagawa PA,Williams SA,et al.Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro[J].Blood,2003, 102(3):887-895
[19]McMillan R,Wang L,Tomer A,et al.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J].Blood,2004,103 (4):1364-1369
[20]侯明.成人特发性血小板减少性紫癜诊断治疗专家共识[J].中华血液学杂志,2009,30(9)：647-648
[21]Jubelirer SJ,Harpold R.The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura:case series and literature review[J].CIin Appl Thromb Hemost,2002, 8(1):73-76
[22]Wang ZY,Shen ZX.Megakaryocytes and platelets in immune thrombocytopenic purpura [J]. Baillieres Clin Haematol.1997,10(1):89-107
[23]唐雪梅,唐晓兰,何文华,等.特发性血小板减少性紫癜90例骨髓与疗效分析[J].四川医学,2002,23(2)：177
[24]British Committee for Standards in Haematology General Haematology Task Force. Guide-lines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J].Br J Haematol,2003,120(4):574-596
[25]朱雪明,顾志成,王兴东.儿童特发性血小板减少性紫癜脾脏组织的病理形态学研究[J].临床小儿外科杂志,2005,4(4)：259-262转265
[1]Arnott J,Horsewood P,Kelton JGMeasurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia[J].Blood,1987,69(5):1294-1299
[2]Stenberg PE,Levin J,Corash L. Sustained thrombocytopenia in mice:serial studies of mega-karyocytes and platelets[J].Exp Hematol.1990,18(2):124-132
[3]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志,1994,15(3)：160-161
[4]Alves-Rosa F, Stanganelli C, Cabrera J, et al. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model[J].Blood,2000,96(8):2834-2840
[5]富琦,范颖,王家辉,等.免疫性血小板减少性紫癜病证结合动物模型建立与评价[J].中国中医基础医学杂志.2004,10(2)：30-32
[6]Wei H,Ding X,Ren J,et al.A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen[J].J Genet Genomics.2008,35(11):665-671
[7]张谊之,王琳,陈娘,等.白塞病皮损中淋巴细胞凋亡和Fas、 Bcl-2的表达[J].临床皮肤科杂 志.2002,3 1(2)：72-74
[8]Mosmann TR,Sad S.The expanding universe of T-cell subsets:Thl,Th2 and more[J]. Immunol Today.1996,17(3):138-146
[9]Romangnani S.Th1 and Th2 in human diseases[J].Clin Immunol Immunopath.1996,80(3):225-235
[10]Newton C, Klein T, Friedman H.The role of macrophages in THC-induced alteration of the cytokine network[J].Adv Exp Med Biol,1998,437:207-214
[11]Haggqvist B, Hultman P.Effects of deviating the Th-2 response in murine mercury-induced autoimmunity towards a Thl-response[J].Clin Exp Immunol,2003,134(2):202-209
[12]Mosmann TR,Kobie JJ,Lee FEH,et al.T helper cytokine patterns:defined subsets, random expression, and external modulation[J].Immunol Res.2009,45:173-184
[13]Nakamura T,Lee RK,Nam SY, et al. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and2 phenotype[J].JImmunol,1997,158(6):2648-2653
[14]Maneti R,Parrinchi P,Giudizi M,et al.Natural killer cell stimulatory factor (Interleukin-12[IL-12]) induces T helper type1(Thl)-specific immune responses and inhibitis the development of IL-4 producing Th cells[J].J Exp Med,1993,177(4):1199-1204
[15]魏海明,刘志,田志刚,等.检测Th1/Th2亚群的意义[J].中华医学检验杂志.1998,21(1)：56-59
[16]陈素娟,孙晓丽,董晓军,等.白细胞介素-4生物学功能及其临床应用[J].标记免疫分析与临床,2003,10(1)：37-39
[17]龚非力主编.医学免疫学[M].第2版.北京：科学出版社,2004.61-84
[18]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346(13): 995-1008
[19]McMillan R.The Pathogenesis of Chronic Immune Thrombocytopenic Purpura[J].Semin Hematol,2007,44(Suppl 5):3-11
[20]Zhou B,Zhao H,Yang RC,et al.Multi-dysfunctional pathophysiology in ITP[J].Crit Rev Oncol Hematol,2005,54(2):107-116
[21]Cooper N,Bussel J.The pathogenesis of immune thrombocytopaenic purpura[J].Br J Haematol, 2006,133(4):364-374
[22]Chanock S.The etiology of childhood immune thrombocytopenic purpura:how complex is it?[J].J Pediatr Hematol Oncol,2003,25(Suppl 1):S7-10
[23]Mouzald A,Theodoropoulou M,Gianakopoulos I,et al.Expression patterns of Thl and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura(ITP) at presentation and their modulation by intravenous immunoglobulin G(ⅣIg) treatment:their role in prognosis[J].Blood, 2002,100(5):1774-1779
[24]Panitsas FP,Theodoropoulou M,Kouraklis A,et al.Adult chronic idiopathic thrombocytopenic purpura(ITP) is the manifestation of a type-1 polarized immune response[J].Blood,2004,103 (7):2645-2647
[25]Ogawara H, Handa H, Morita K,et al. High Thl/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol,2003,71(4):283-288
[26]Semple JW,Milev Y,Cosgrave D,et al.Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity[J].Blood,1996,87(10):4245-4254
[27]Panitsas FP,Kouraklis A.Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP)[J].BMC Blood Disord,2004,4(1):4
[28]王宁玲,戴海明,祝怀平,等.特发性血小板减少性紫癜患儿Thl/Th2相关细胞因子的检测[J].中华血液学杂志,2002,23(9)：486-487
[29]阮积晨,赵芹,周海霞,等.特发性血小板减少性紫癜患儿Th亚群细胞因子的检测[J].中国小儿血液与肿瘤杂志,2006,11(4)：22-24
[30]杨小猛,刘仿,陈群,等.特发性血小板减少性紫癜患儿Thl/Th2、Tc1/Tc2亚群漂移的研究[J].中国免疫学杂志,2005,21(1)：76-79
[31]Crossley AR,Dickinson AM,Proctor SJ,et al.Effects of interferon-a therapy on immune parameters in immune thrombocytopenic purpura[J].Autoimmunity.1996,24(2):81-100
[32]Webber NP,Mascarenhas JO,Crow MK,et al. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura[J].Hum Immunol.2001,62(12):1346-1355
[33]王国兵,李成荣,李长钢,等.儿童急性ITP Th1/Th2细胞功能状态初步研究[J].中国小儿血液与肿瘤杂志,2008,13(4)：156-160
[34]Letterio JJ,Roberts AB.Regulation of immune responses by TGF-beta[J].Ann Rev Immunol, 1998,16:137-161
[35]Fukaura H, Kent SC, Pietrusewicz MJ,et al.Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-betal-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients[J].Journal of Clinical Investigation, 1996,98(1):70-77
[36]Bridoux F,Badou A,Saoudi A,et al.Transforming growth factor-β(TGF-β)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex(MHC) class II-specific,regulatory CD4+T cell lines[J].J Exp Med,1997,185(10):1769-1775
[37]Chen Y, Kuchroo VK,Inobe J,et al.Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis[J].Science,1994,265(5176):1237-1240
[38]Cross D,Cambier JC.Transforming growth factor beta-1 has differential effects on B cell proliferation and activation antigen expression[J].J Immunol,1990,144:432-439
[39]Gorelik L.Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease[J].Immunity,2000,12(2):171-181
[40]Fortunel N,Hatzfeld J,Kisselev S,et al.Release from quiescence of primitive human hemato- poietic stem/progenitor cells by blocking their cell-surface TGF-beta type Ⅱ receptor in a short-term in vitro assay[J].Stem Cells,2000,18(2):102-111
[41]Atabay B,Oren H,Irken Qet al.Role of transforming growth factor-beta 1 gene polymerphisms in childhood idiopathic thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2003,25(11):885-889
[42]Fortunel NO,Hatzfeld A,Hatzfeld JA.Transforming growth factor-beta:pleiotropic role in the regulation of hematopoiesis[J].Blood,2000,96(6):2022-2036
[43]Sakamaki S,Hirayama Y,Matsunaga T,et al.Transforming growth factor-β1(TGF-β1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-(3 receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-P itself with high specificity[J].Blood,1999,94(6):1961-1970
[44]鞠秀丽,丁红芳,魏伟,等.血小板生成素和转化生长因子-β1与儿童特发性血小板减少性紫癜的相关性研究[J].中国实用儿科杂志,2004,19(11)：663-665
[45]Andersson PO, Stockelberg D, et al. A transforming growth factor-betal-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura[J].Ann Hematol,2000,79(9):507-513
[46]Fahim NM, Monir E.Functional role of CD4+CD25+regulatory T cells and transforming growth factor-betal in childhood immune thrombocytopenic purpura[J].Egypt J Immunol.2006, 13(1):173-187
[47]Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol.1995,155 (3):1151-1164
[48]Picca CC, Caton AJ.The role of self-peptides in the development of CD4+CD25+regulatory T cells[J].Curr Opin Immunol,2005,17(2):131-136
[49]Piccirillo CA, Thornton AM. Cornerstone of peripheral tolerance:naturally occurring CD4+CD25+regulatory T cells[J].Trends Immunol,2004,25(7):374-380
[50]Sakaguchi S, Sakaguchi N,Shimizu J,et al.Immunologic tolerance maintained by CD4+CD25+ regulatory T cells:their common role in controlling autoimmunity,tumor immunity,and trans-plantation tolerance[J].Immunol Rev,2001,182(1):18-32
[51]Lan RY,Ansari AA,Lian ZX,et al.Regulatory T cells:development,function and role in auto-immunity [J].Autoimmu Rev,2005,4(6):351-363
[52]Hori S, Nomura T, Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science,2003,299(5609):1057-1061
[53]Fontenot JD,Gavin MA,Rudensky AYFoxp3 programs the development and function of CD4+CD25+regulatory T cells[J].Nat Immunol,2003,4(4):330-336
[54]Shevach EM.Certified professionals:CD4+CD25+suppressor T cells[J].J Exp Med.2001,193 (11):F41-45
[55]Thompson C,Powrie F.Regulatory T cells[J].Curr Opin Pharmacol.2004,4(4):408-414
[56]Sakaguchi S,Yamaguchi T,Nomura T,et al.Regulatory T Cell and Immune Tolerance[J].Cell, 2008,133(5):775-787
[57]Taams LS,van Amelsfort JM,Tiemessen MM,et al.Modulation of monocyte/macrophage function by human CD4+CD25+regulatory T cells[J].Hum Immunol.2005,66(3):222-230
[58]Chatila TA.Role of regulatory T cells in human diseases[J].J Allergy Clin Immunol,2005,116 (5):949-959
[59]Sakaguchi S.Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses[J].Allnu Rev Immunol,2004,22:531-562
[60]Horwitz DA,Zheng SQGray JD.The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+CD25+ and CD8+ regulatory T cells subsets [J].Leukoc Biol,2003,74(4):471-478
[61]Cederbom L,Hall H,Ivars F.CD4+CD25+regulatory T cells down-regulate co-stimuatory molecules on antigen-presenting cells[J].Eur J Immunol,2000,30(6):1538-1543
[62]Kursar M,Bonhagen K,Fensterle J,et al.Regulatory CD4+CD25+T cells restrict memory CD8+T cell responses[J].J Exp Med,2002,196(12):1585-1592
[63]Azuma T,Takahashi T,Kunisato A,et al.Human CD4+CD25+regulatory T cells.suppess NKT cell fiinction[J].Cancer Res,2003,63(15):4516-4520
[64]Lim HW,Hillsamer P,Banham AH,et al.Cutting edge:Direct suppression of B cells by CD4+CD25+regulatory T cells[J].J Immunol,2005,175(7):4180-4183
[65]Zhao DM,Thornton AM,Dipaolo RJ,et al.Activated CD4+CD25+T cells selectively kill B lymphocytes[J].Blood,2006,107(10):3925-3932
[66]Hsu WT,Suen JL,Chiang BL.The role of CD4+D25+T cells in autoantibody production in murine lupus[J].Clin Exp Immunol,2006,145(3):513-519
[67]何伟刚,曹雪涛.CD4+CD25+调节性T细胞与负向免疫调控及免疫耐受[J].国际肿瘤学杂志,2006,33(5)：324-328
[68]Balandina A,Lecart S,Dartevelle P,et al.Functional defect of regulatory CD4+CD25+T cells in the thymus of patients with autoimmune myasthenia gravis[J].Blood,2005,105 (2):735-741
[69]Lin SC,Chen KH,Lin CH,et al.The quantitative analysis of peripheral blood Foxp3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients[J].Eur J Clin Invest,2007,37(12):987-996
[70]Jiao Z,Wang WJia R,et al.Accumulation of Foxp3-expressing CD4+CD25+T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis [J].Scand J Rheumatol.2007,36(6):428-433
[71]Kemeny DM, Macary PA.The growing complexity of TGF-beta as a T-cell regulator [J]. Immunology,2005,114(4):459-460
[72]Nakamura K,Kitani A,Strober W.Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factorβ[J] J Exp Med. 2001,194(5):629-644
[73]Nakamura K,Kitani A,Fuss I,et al.TGF-β1 plays an important role in the mechanism of CD4+CD25+regulatory T cell activity in both humans and mice[J].J Immunol.2004,172(2): 834-842
[74]Huber S,Schramm C.TGF-beta and CD4+CD25+regulatory T cells[J].Front Biosci,2006,11 (1):1014-1023
[75]Yamagiwa S,Gray JD,Hashimoto S,et al.A role for TGF-beta in the generation and expansion of CD4+CD25+regulatory cells from human peripheral blood[J].J Immunol.2001,166(12): 7282-7289
[76]Pyzik M,Piccirillo CA.TGF-betal modulates Foxp3 expression and regulatory activity in distinct CD4+T cell subsets[J].J Leukoc Biol,2007,82(2):335-346
[77]Strauss L,Bergmann C,Szczepanski M,et al.A unique subset of CD4+CD25 high Foxp3+T Cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment[J].Clin Cancer Res,2007,13(15):4345-4354
[78]Von Boehmer H.Mechanisms of suppression by suppressor T cells[J].Nat Immunol,2005,6(4): 338-344
[79]Zhang L,Yi H,Xia XP,et al.Transforming growth factor-beta:an important role in CD4+CD25+ regulatory T cells and immune tolerance[J].Autoimmunity,2006,39(4):269-276
[80]Sakakura M,Wada H,Tawara I,et al.Reduced CD4+CD25+T cells in patients with idiopathic thrombocytopenic purpura[J].Thromb Res.2007,120(2):187-193
[81]Liu B,Zhao H,Poon MC,et al.Abnormality of CD4+CD25+regulatory T cells in idiopathic thrombocytopenic purpura[J].Eur J Haematol.2006,78(2):139-143
[82]Pinkoski MJ,Waterhous NJ,Green DR. Mitochondria,apoptosis and autoimmunity[J].Curr Dir Autoimmun,2006,9:55-73
[83]Perfettini JL,Roumier T,Kroemer GMitochondrial fusion and fission in the control of apoptosis [J].Trends Cell Biol,2005,15(4):179-183
[84]Derfuss T,Fickenscher H,Kraft MS,et al.Antiapoptotic activity of the herpervirus saimiri-encoded Bcl-2 homolog:stabilization of mitochondria and inhibition of caspase-3-like activity [J].J Virol,1998,72(7):5897-5904
[85]Adams JM,Cory S.The Bcl-2 protein family:Abiters of cell survival[J].Science,1998,281 (5381):1322-1326
[86]Petros AM,Olejniczak ET,Fesik SW.Structural biology of the Bcl-2 family of proteins[J]. Biochim Biophys Acta,2004,1644(2-3):83-94
[87]Cosulich SQWorrall V,Hedge PJ,et al.Regulation of apoptosis by BH3 domains in a cell-free system[J].Curre Biol,1997,71(12):913-920
[88]Breckenridge DG, Xue D.Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases[J].Curr Opin Cell Biol,2004,16(6):647-652
[89]Sharpe JC, Arnoult D,Youle RL.Crontrol of mitochondrial permeability by Bcl-2 family members[J].Biochim Bionhys Acta,2004,1644(2-3):107-113
[90]Rosse T,Olivier R,Monney L,et al.Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c [J].Nature.1998,391(6666):496-499
[91]周桔,罗荣保,汤长发,等.Bcl-2蛋白家族和p53基因在细胞凋亡中的调控效应[J].中国组织工程研究与临床康复,2007,11(10)：1950-1952
[92]Kuwana,Newmeyer.Bcl-2 family proteins and the role of mitochondria in apoptosis[J]. Curr Opin Cell Biol,2003,15(4):691-699
[93]Lalier L,Cartron PF,Juin P,et al.Bax activation and mitochondrial insertion during apoptosis[J]. Apoptosis,2007,12(5):887-896
[94]Korsmeyr SJ.Bcl-2 gene family and the regulation of programmed cell death[J].Cancer Res.1999,59(7Suppl):1693-1700
[95]Eguchi K.Apoptosis in autommune diseases[J].Inter Med.2001,40(4):275-284
[96]Olsson B, Andersson PO,Jacobsson S,et al.Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura[J].Thromb Haemost.2005,93(1):139-144
[97]Wu CL,Liu F,Zhou XM,et al.Effect of protein kinase C on proliferation and apoptosis of T lymphocytes in idiopathic thrombocytopenic purpura children[J].Cell Mol Immunol,2005,2(3): 197-203
[98]Liu F,Wu CL,Yang XM,et al.Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura[J].Cell Mol Immunol.2005,2(5):387-392
[99]刘仿,肖红,孟琼,等.特发性血小板减少性紫癜淋巴细胞凋亡及凋亡蛋白表达的研究[J].中国免疫学杂志.2004,20(3)：202-205
[100]Yoshimura C,Nomura S,Nagaham M,et al.Plasma-soluble Fas (APO-1、CD95) and soluble Fas ligand in immune thrombocytopenic purpura[J].Eur J Haematol,2000,64(4):219-224
[101]王开颜,房崇芸,彭光洁.氢化可的松诱导特发性血小板减少性紫癜淋巴细胞凋亡和增殖抑制[J].中国组织化学与细胞化学杂志,2000,9(2)：149-151
[2]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346(13): 995-1008
[3]Cines DB,McMillan R.Pathogenesis of chronic immune thrombocytopenic purpura [J].Curr Opin Hematol,2007,14(5):511-514
[4]Rodeghiero F,Stasi R,Gernsheimer T,et al.Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children:report from an international working group[J].Blood,2009,113(11):2386-2393
[5]Provan D,Stasi R,Newland AC,et al.International consensus report on the investigation and management of primary immune thrombocytopenia[J].Blood,2010,115(2):168-186
[6]Nugent D,McMillan R,Nichol NL,et al.Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production[J].Bri J Haematol,2009,146: 585-596
[7]Chang M,Nakagawa PA,Williams SA,et al.Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro[J]. Blood,2003, 102(3):887-895
[8]McMillan R,Wang L,Tomer A,et al.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J].Blood,2004,103(4):1364-1369
[9]Zhou B,Zhao H,Yang RC,et al.Multi-dysfunctional pathophysiology in ITP[J].Crit Rev Oncol Hematol,2005,54(2):107-116
[10]Gernsheimer T.Epidemiology and pathophysiology of immune thrombocytopenic purpura [J].Euro J Haematol,2008,80(Suppl 69):3-8
[11]Gernsheimer T.Chronic idiopathic thrombocytopenic purpura:mechanisms of pathogenesis[J]. The Oncologist,2009,14 (1):12-21
[12]Harrington WJ,Minnich V,Hollingsworth JW,et al.Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura[J].J Lab Clin Med,1951,38(1):1-10
[13]Shulman NR,Marder VJ,Weinrach RS.Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura.Physiologic, serologic and isotopic studies[J].Ann N Y Acad Sci,1965,124 (2):499-542
[14]Shulman NR,Weinrach RS,Libre EP,et al.The role of the reticuloendothelial system in the pathogenesis of idiopathic thrombocytopenic purpura[J].Trails Assoc Am Physicians,1965,78: 374-390
[15]McMillan R, Smith RS,Longmire RL,et al.Immunoglobulins associated with human platelets, [J].Blood,1971,37(3):3163-3122
[16]Dixon R,Rosse W,Ebbert L.Quantitative determination of antibody in idiopathic thrombocyto-penic purpura. Correlation of serum and platelet-bound antibody with clinical response[J].N Engl J Med,1975,292:230-236
[17]McMillan R,Tani P,Millard F,et al. Platelet-associated and plasma anti-glycoprotein autoanti-bodies in chronic ITP[J].Blood,1987,70(4):1040-1045
[18]Kiefel V, Santoso S, Kaufmann E, et al.Autoantibodies against platelet glyco-protein Ib/IX:a frequent finding in autoimmune thrombocytopenic purpura[J].Br J Haematol,1991,79(2):256-262
[19]Woods VL, Oh EH, Mason D,et al. Autoantibodies against the platelet glyco-protein Ⅱb/Ⅲa complex in patients with chronic ITP[J].Blood,1984,63 63(2):368-375
[20]Hou M, Stockelberg D, Kutti J,et al.Antibodies against platelet GPⅠb/Ⅸ, GPⅡb/Ⅲa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol,1995,55 (5):307-314
[21]Brighton TA,Evans S,Castaldi PA,et al.Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias[J].Blood,1996,88(1):194-201
[22]McMillan R.The Pathogenesis of Chronic Immune Thrombocytopenic Purpura[J].Semin Hematol,2007,44(suppl 5):S3-S11
[23]王同保,赵金枝,张欣欣,等.血小板抗体对原发性血小板减少性紫癜巨核细胞成熟发育的影响[J].中华儿科杂志,1995,33(2)：112-113
[24]王萍萍,卢香兰,李霞.血小板相关抗体对原发性血小板减少性紫癜患者巨核细胞数量及成熟程度的影响[J].中国医科大学学报,2003,32(4)：348-350
[25]Houwerzijl EJ,Blom NR,vail der Want JJ,et al.Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thromboeytopenic purpura[J].Blood,2004,103(2):500-506
[26]Stahl CP, Zucker-Franklin D, McDonald TP. Incomplete antigenic cross-reactivity between platelets and megakaryocytes:relevance to ITP[J].Blood,1986,67(2):421-428
[27]Moore PA,Belvedere O,Orr A,et al.BLyS:member of the tumor necrosis factor family and B lymphocyte stimulator[J].Science,1999,285(5425):260-263
[28]Schneider P,MacKay P,Steiner V,et al.BAFF,an novel ligand of the tumor necrosis factor family,stimulates B cell growth[J].J Exp Med,1999,189(11):1747-1756
[29]Schneider P,Tschopp J.BAFF and the regulation of B cell survival[J].Immunol Lett,2003:88 (1):57-62
[30]Emmerich F,Bal QBarakat A,et al.High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura[J].Br J Haematol,2006, 136(2):309-314
[31]Zhou ZP,Chen ZP,Li HQ,et al.BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura[J].Autoimmunity,2009,42(2):112-119
[32]Zhu XJ,Shi Y,Peng J,et al.The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia[J].Blood,2009,114(26):5362-5367
[33]Arfors L,Winiarski J,Lefvert AK.Prevalence of antibodies to cardiolipin in chronic ITP and reactivity with platelet membranes[J].Eur J Haematol,1996,56(4):230-234
[34]Stasi K,Stipa E,Masi M, et al.Prevalence and clinical significance of elevated anti-phos-pholipid antibodies in patients with idiopathic thrombocytopenic purpura[J].Blood,1994,84(12): 4203-4208
[35]Love PE, Santoro SA.Antiphospholipid antibodies:anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders.Prevalence and clinical significance[J].Ann Intern Med,1990,112(9):682-698
[36]李一荣,姜伟超,邢辉,等.慢性特发性血小板减少性紫ANA和ACA的检测及临床意义[J].临床血液学杂志,2003,16(6)：286-287
[37]Galli M,Daldossi M,Barbui T. Anti-glycoprotein Ⅰb/Ⅸ and Ⅱb/Ⅲa antibodies in patients with antiphospholipid antibodies[J].Thromb Haemost,1994,71(5):571-575
[38]van Leeuwen EF,van der Ven JT,Engelfriet CP. Specificity of autoantibodies in auto-immune thrombocytopenia[J].Blood,1982,59(1):23-26
[39]McMillan R.Autoantibodies and autoantigens in chronic immune thrombocytopenic purpura [J].Semin Hematol,2000,37(3):239-248
[40]Escher R,Muller D,Vogel M, et al.Recombinant human natural autoantibodies against GPIlb/ Ⅲa inhibit binding of autoantibodies from patients with AITP[J].Br J Haematol,1998,102 (3):820-828.
[41]Kuwana M,Kaburaki J,Kitasato H,et al.Immunodominant epitopes on glycoprotein Ⅱb/Ⅲa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura[J].Blood, 2001,98(1):130-139
[42]McMilla R,Lopez-Dee J,Bowditch R.Clonal restriction of platelet-associated anti-GP Ⅱb/Ⅲa autoantibodies in patients with chronic ITP[J].Thromb Haemost,2001,85 (5):821-823'
[43]Beardsley DS.ITP in the 21st century.Hematology Am Soc Hematol Educ Program.2006: 402-407
[44]Abbas AK,Murphy KM,Sher A.Functional diversity of helper T lymphocytes[J].Nature,1996, 383(6603):787-793
[45]Semple JW, Freedman J.Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia[J].Blood,1991,78(10):2619-2625
[46]Semple JW, Milev Y, Cosgrave D, et al.Difference in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity[J].Blood,1996,87(10):4245-4254
[47]Kuwana M, Kaburaki J, Ikeda Y.Autoreactive T cells to platelet GPⅡb-Ⅲa in immune thrombocytopenic purpura:role in production of antiplatelet autoantibody[J].J Clin Invest,1998, 102(7):1393-1402
[48]Ware RR,Howard TA.Phenotypic and clonal analysis of T lymphocytes in childhood immune thrombocytopenic purpura[J].Blood,1993,82(7):2137-2142
[49]Filion MC,Bradley AJ,Devine DV,et al.Autoreactive T cells in healthy individuals show tolerance in vitro with characteristics similar to but distinct from clonal anergy[J].Eur J Immunol,1995,25(11):3123-3127
[50]Shimomura T, Fujimura K, Takafuta T, et al.Oligoclonal accumulation of T cells in peripheral blood from patients with idiopathic thrombocytopenic purpura[J].B J Haematol.1996,95(4):732-737
[51]Roark JH,Bussel JB,Cines DB,et al.Genetic analysis of autoantibodies in idiopathic thrombo-cytopenic purpura reveals evidence of clonal expansion and somatic mutation[J].Blood,2002, 100(4):1388-1398
[52]Garcia-Suarez J,Prieto A,Reyes E,et al.Abnormal γIFN and aTNF secretion in purified CD2+ cells from autoimmune thrombocytopenic purpura (ATP) patients:Their implication in the clinical course of the disease[J].Am J Hematol,1995,49(4):271-276
[53]Yoshimura C,Nomura S,Nagahama M,et al.Plasmasoluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura[J].Eur J Haematol,2000,64 (4):219-224
[54]Lechler R,Chai JQMarelli-Berg F,et al.The contributions of T-cell anergy to peripheral T-cell tolerance [J].Immunology,2001,103(3):262-269
[55]Koshy M, Berger D,Crow MK.Icreased expression of CD40 ligand on systemic lupus erythematosus lymphocytes[J].J Clin Invest,1996,98(3):826-837
[56]Czapiga M,Kirk AD,Lekstrom-Himes J.Platelets deliver costimulatory signals to antigen-presenting cells:a potential bridge between injury and immune activation[J].Exp Hematol,2004,32 (2):135-139
[57]Henn V,Slup sky JR,Grafe M,et al.CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells[J].Nature,1998,391(6667):591-594
[58]WebberNP, Mascarenhas JO,CrowMK, et al.Functional properties of lymphocytes in idiopathic thrombocytopenic purpura[J].Hum Immunol,2001,62(12):1346-1355
[59]Solanilla A,Pasquet JM,Viallard JF,et al.Platelet-associated CD154 in immune thrombocyto-penic purpura[J].Blood,2005,105(1):215-218
[60]Meabed MH,Taha GM,Mohamed SO,et al.Autoimmune thrombocytopenia:flow cytometric determination of platelet-associated CD154/CD40L and CD40 on peripheral blood T and B lymphocytes[J].Hematology,2007,12(4):301-307
[61]Nagahama M, Nomura S, Kanazawa S, et al.Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura[J].Eur J Haematol,2002,69(5-6): 303-308
[62]赵艳霞,高清平,陈友华,等.特发性血小板减少性紫癜患者外周血淋巴细胞协同刺激分子的表达[J].中华血液学杂志,2003,24(9)：474-476
[63]Fan Y,Ge Y,Zhu H,et al.Characterization and application of two novel monoclonal antibodies against CD40L:epitope and functional studies on cell membrane CD40L and studies on the origin of soluble serum CD40L [J].Tissue Antigens,2004,64(3):257-263
[64]Zhang XL, Peng J, Sun JZ,et al. Modulation of immune response with cytotoxic T-lymphocyte-associated antigen 4 immunoglobulin-induced anergic T cells in chronic idiopathic thrombocytopenic purpura[J].J Thromb Haemost,2008,6(1):158-165
[65]Catani L, Fagioli ME, Tazzari PL, et al.Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes [J].Exp Hematol, 2006,34(7):879-887
[66]Kuwana M, Kawakami Y, Ikeda Y. Suppression of autoreactive T-cell response to glycoprotein Ⅱb/Ⅲa by blockade of CD40/CD154 interaction:implications for treatment of immune thrombocytopenic purpura[J].Blood,2003,101 (2):621-623
[67]Hou M,Peng J,Shi Y, et al.Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura[J].Eur J Haematol,2003,70(6):353-357
[68]Peng J,Liu C,Liu D,et al. Effects of B7-blocking agent and/or CsA on induction of platelet-specific T-cell anergy in chronic autoimmune thrombocytopenic purpura [J].Blood,2003,101 (7):2721-2726
[69]Mosmann TR,Sad S.The expanding universe of T-cell subsets:Th1,Th2 and more[J]. Immunol Today.1996,17(3):138-146
[70]Romangnani S.Thl and Th2 in human diseases[J].Clin Immunol Immunopath.1996,80(3 Pt 1): 225-235
[71]Newton C,Klein T,Friedman H.The role of macrophages in THC-induced alteration of t he cytokine network[J].Adv Exp Med Biol,1998,437:207-214
[72]Haggqvist B,Hultman P.Effects of deviating the Th-2 response in murine mercury-induced autoimmunity towards a Thl-response[J].Clin Exp Immunol,2003,134(2):202-209
[73]Mosmann TR,Kobie JJ,Lee FEH,et al.T helper cytokine patterns:defined subsets, random expression, and external modulation[J].Immunol Res.2009,45(2-3):173-184
[74]魏海明,刘志,田志刚,等.检测Thl／Th2亚群的意义[J].中华医学检验杂志.1998,21(1)：56-59
[75]Nakamura T,Lee RK,Nam SY,et al. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and 2 phenotype[J].J Immunol,1997,158(6):2648-2653
[76]Maneti R,Parrinchi P,Giudizi M,et al.Natural killer cell stimulatory factor (Interleukin-12 [IL-12]) induces T helper type1(Thl)-specific immune responses and inhibitis the development of IL-4 producing Th cells[J].J Exp Med,1993,177(4):1199-1204
[77]Liblau RS,Singer SM,Mcdevitt HO.Thl and Th2 CD4+T cells in the pathogenesis of organ-specific autoimmune disease[J].Immunol Today.1995,16(1):34-38
[78]Matsuzaki J, Tsuji T, Imazeki I,et al.Immunosteroid as a regulator for Thl/Th2 balance:Its possible[J].Autoimmunity,2005,38(5):369-375
[79]Chanock S.The etiology of childhood immune thrombocytopenic purpura:how complex is it?[J].J Pediatr Hematol Oncol,2003,25(Suppl 1):S7-10
[80]Mouzaki A,Theodoropoulou M,Gianakopoulos I,et al.Expression patterns of Thl and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura(ITP) at presentation and their modulation by intravenous immunoglobulin G(IVIg) treatment:their role in prognosis[J]. Blood,2002,100(5):1774-1779
[81]Panitsas FP,Theodoropoulou M,Kouraklis A,et al.Adult chronic idiopathic thrombocytopenic purpura(ITP) is the manifestation of a type-1 polarized immune response [J].Blood,2004,103 (7):2645-2647
[82]Ogawara H,Handa H,Morita K,et al.High Thl/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol,2003,71(4):283-288
[83]Panitsas FP,Kouraklis A.Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP)[J].BMC Blood Disord,2004,4(1):4
[84]Olsson B,Andersson PO,Jernas M,et al.T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura[J].Nat Med,2003,9(9):1123-1124
[85]王宁玲,戴海明,祝怀平,等.特发性血小板减少性紫癜患儿Th1/Th2相关细胞因子的检测[J].中华血液学杂志,2002,23(9)：486-487
[86]阮积晨,赵芹,周海霞,等.特发性血小板减少性紫癜患儿Th亚群细胞因子的检测[J].中国小儿血液与肿瘤杂志,2006,11(4)：22-24
[87]杨小猛,刘仿,陈群,等.特发性血小板减少性紫癜患儿Th1/Th2. Tc1/Tc2亚群漂移的研究[J].中国免疫学杂志,2005,21(1)：76-79
[88]Crossley AR,Dickinson AM,Proctor SJ,et al.Effects of interferon-a therapy on immune parameters in immune thrombocytopenic purpura[J].Autoimmunity.1996,24(2):81-100
[89]Lazarus AH,Ellis J,Semple JW,et al. Comparison of platelet immunity in patients with SLE and with ITP[J].Transfus Sci.2000,22(1-2):19-27
[90]王国兵,李成荣,李长钢,等.儿童急性ITPTh1/Th2细胞功能状态初步研究[J].中国小儿血液与肿瘤杂志,2008,13(4)：156-160
[91]谭柏林,赵谢兰,尹楚兰.特发性血小板减少性紫癜患者IL-2受体的变化[J].湖南医科大学学报，1998,23(2)：191-193
[92]Erduran E,Aslan Y,Aliyazicioglu Y,et al.Plasma soluble interleukin-2 receptor levels in patients with idiopathic thrombocytopenic purpura[J].Am J Hematol.1998,57:119-123
[93]Letterio JJ,Roberts AB.Regulation of immune responses by TGF-beta[J].Ann Rev Immunol,1998,16:137-161
[94]Fukaura H, Kent SC, Pietrusewicz MJ,et al.Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients[J].J Clin Invest,1996,98(1):70-77
[95]Bridoux F,Badou A,Saoudi A,et al.Transforming growth factorβ(TGF-β)-dependent inhibition of T helper cell 2(Th2)-induced autoimmunity by self-major histocompatibility complex (MHC) class Ⅱ-specific,regulatory CD4+T cell lines[J].J Exp Med,1997,185(10):1769-1775
[96]Chen Y, Kuchroo VK,Inobe J,et al.Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis[J].Science,1994,265(5176):1237-1240
[97]Cross D,Cambier JC.Transforming growth factor betal has differential effects on B cell proliferation and activation antigen expression[J].J Immunol,1990,144(2):432-439
[98]Gorelik L.Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease[J].Immunity,2000,12(2):171-181
[99]Sakamaki S,Hirayama Y,Matsunaga T,et al.Transforming growth factor-β1 (TGF-β1) induces thrombopoietin from bone marrow stromal cells,which stimulates the expression of TGF-β receptor on megakaryocytes and,in turn,renders them susceptible to suppression by TGF-β itself with high specificity[J].Blood,1999,94(6):1961-1970
[100]鞠秀丽,丁红芳,魏伟,等.血小板生成素和转化生长因子-β1与儿童特发性血小板减少性紫癜的相关性研究[J].中国实用儿科杂志,2004,19(11)：663-665
[101]Andersson PO,Stockelberg D,Jacobsson S,et al.A transforming growth factor-β1-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura[J].Ann Hematol,2000,79(9):507-513
[102]Fahim NM, Monir E.Functional role of CD4+CD25+regulatory T cells and transforming growth factor-betal in childhood immune thrombocytopenic purpura[J].Egypt J Immunol.2006, 13(1):173-187
[103]Boshkov LK,Kelton JQHalloran PF. HLA-DR expression by platelets in acute idiopathic thrombocytopenic purpura[J].Br J Haematol,1992,81(4):552-557
[104]Semple JW,Mitelman B,Allen D,et al. Platelet HLA-DR expression is mediated by physical interaction with adherent CD 14+macrophages:Possible role in the pathogenesis of autoimmune thrombocytopenia[J].Blood,1995,86:2148(suppl,abstr)
[105]王林,张峰,朱媛媛,等.特发性血小板减少性紫癜患者自身血小板的细胞毒杀伤机制[J].中华医学杂志,2005,85(43)：3048-2053
[106]Adams JM,Cory S.The Bcl-2 protein family:Abiters of cell survival[J].Science,1998, 281(5381):1322-1326
[107]Petros AM,Olejniczak ET,Fesik SW.Structural biology of the Bcl-2 family of proteins[J]. Biochim Biophys Acta,2004,1644(2-3):83-94
[108]Cosulich SQWorrall V,Hedge PJ,et al.Regulation of apoptosis by BH3 domains in a cell-free system[J].Curre Biol,1997,71(12):913-920
[109]Breckenridge DQXue D.Regulation of mitochondrial membrane permeabilization by Bcl-2 family proteins and caspases[J].Curr Opin Cell Biol,2004,16(6):647-652
[110]Sharpe JC,Arnoult D,Youle RL.Crontrol of mitochondrial permeability by Bcl-2 family members[J].Biochim Bionhys Acta,2004,1644(2-3):107-113
[111]Rosse T,Olivier R,Monney L,et al.Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c[J].Nature.1998,391(6666):496-499
[112]周桔,罗荣保,汤长发,等.Bcl-2蛋白家族和p53基因在细胞凋亡中的调控效应[J].中国组织工程研究与临床康复,2007,11(10)：1950-1952
[113]Kuwana,Newmeyer.Bcl-2 family proteins and the role of mitochondria in apoptosis[J].Curr Opin Cell Biol,2003,15(4):691-699
[114]Lalier L,Cartron PFJuin P,et al.Bax activation and mitochondrial insertion during apoptosis [J].Apoptosis.2007,12(5):887-896
[115]Korsmeyr SJ.Bcl-2 gene family and the regulation of programmed cell death [J].Cancer Res.1999,59(7Suppl):1693-1700
[116]Eguchi K.Apoptosis in autommune diseases[J].Inter Med.2001,40(4):275-284
[117]Olsson B,Andersson PO, Jacobsson S,et al.Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura[J].Thromb Haemost,2005,93(1):139-144
[118]王琼玉,高清平.细胞凋亡和增殖在特发性血小板减少性紫癜中的作用[J].临床内科杂志,2003,20(8)：421-423
[119]孟瑞锋,盛光耀,王利.淋巴细胞凋亡异常在AITP患儿中的作用研究[J].医药论坛杂志,2006,27(14)：37-38转41
[120]张静,凌云,曹祥山,等.特发性血小板减少性紫癜患者CD3+、CD4+和CD8+T淋巴细胞凋亡率的研究[J].临床血液学杂志,2009,22(9)：460-462
[121]Moulian N,Renvoize C,Desodt C,et al.Function Fas expression in human themic epithelial cells[J].Blood,1999,93(8):2660-2670
[122]Ju ST,Pomka DJ,Cui H,et al.Fas(CD95)/FasL interaction reguired for programmed cell death T-cell activation[J].Nature,1995,373(6513):444-450
[123]高清平,黄望香,李秀珍.慢性特发性血小板减少性紫癜淋巴细胞和血小板凋亡蛋白的表达[J].临床内科杂志,2001,14(3)：104-106
[124]刘仿,肖红,孟琼,等.特发性血小板减少性紫癜淋巴细胞凋亡及凋亡蛋白表达的研究[J].中国免疫学杂志,2004,20(3)：46-49
[125]Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J].J Immunol.1995,155 (3):1151-1164
[126]Bluestone JA, Abbas AK.Natural versus adaptive regulatory T cells[J].Nat Rev Immunol, 2003,3(3):253-257
[127]Shevach EM.CD4+CD25+Suppressor T cells:more questions than answers[J].Nat Rev Immunol,2002,2(6):389-400
[128]Piccirillo CA,Thornton AM.Cornerstone of peripheral tolerance:naturally occurring CD4+ CD25+regulatory T cells[J].Trends Immunol,2004,25(7):374-380
[129]Takahashi T, Tagami T, Yamazaki S, et al. Immunologic self-tolerance maintained by CD25+CD4+regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4[J].J Exp Med,2000,192(2):303-310
[130]Lan RY,Ansari AA,Lian ZX,et al.Regulatory T cells:development,function and role in autoimmunity[J].AutoimmuRev,2005,4(6):351-363
[131]Hori S, Nomura T, Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science,2003,299(5609):1057-1061
[132]Fontenot JD,Gavin MA,Rudensky AY.Foxp3 programs the development and function of CD4+CD25+regulatory T cells[J].Nat Immunol,2003,4(4):330-336
[133]Shevach EM.Certified professionals:CD4+CD25+suppressor T cells[J].J Exp Med.2001, 193(11):F41-45
[134]Thompson C,Powrie F.Regulatory T cells[J].Curr Opin Pharmacol.2004,4(4):408-414
[135]Sakaguchi S,Yamaguchi T,Nomura T,et al.Regulatory T Cell and Immune Tolerance[J]. Cell. 2008,133(5):775-787
[136]Taams LS,van Amelsfort JM.Tiemessen MM,et al.Modulation of monocytemacrophage function by human CD4+CD25+regulatory T cells[J].Hum Immunol,2005,66(3):222-230
[137]Chatila TA.Role of regulatory T cells in human diseases[J].J Allergy Clin Immunol. 2005,116(5):949-959
[138]Sakaguchi S.Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses[J].Allnu Rev Immunol,2004,22:531-562
[139]Horwitz DA,Zheng SG,Gray JD.The role of the combination of IL-2 and TGF-β or IL-10 in the generation and function of CD4+CD25+and CD8+regulatory T cells subsets[J].J Leukoc Biol,2003,74(4):471-478
[140]Cederbom L,Hall H,Ivars F.CD4+CD25+regulatory T cells down-regulate co-stimulatory molecules on antigen-presenting cells[J].Eur J Immunol,2000,30(6):1538-1543
[141]Kursar M,Bonhagen K,Fensterle J,et al.Regulatory CD4+CD25+ T cells restrict memory CD8+T cell responses[J].J Exp Med,2002,196(12):1585-1592
[142]Azuma T,Takahashi T,Kunisato A,et al.Human CD4+CD25+regulatory T cells suppess NKT cell function[J].Cancer Res,2003,63(15):4516-4520
[143]Lim HW,Hillsamer P,Banham AH,et al.Cutting Edge:Direct Suppression of B Cells by CD4+CD25+Regulatory T Cells[J].J Immunol,2005,175(7):4180-4183
[144]Zhao DM,Thornton AM,Dipaolo RJ,et al.Activated CD4+CD25+T cells selectively kill B lymphocytes[J].Blood,2006,107(10):3925-3932
[145]Hsu WT,Suen JL,Chiang BL.The role of CD4+ D25+ T cells in autoantibody production in murine lupus[J].Clin Exp Immunol,2006,145(3):513-519
[146]何伟刚,曹雪涛.CD4+CD25+调节性T细胞与负向免疫调控及免疫耐受[J].国际肿瘤学杂志,2006,33(5)：324-328
[147]Boehmer H.Mechanisms of suppression by suppressor T cells[J].Nat Immunol,2005,6(4): 338-44
[148]Nakamura K,Kitani A,Strober W.Cell contact-dependent immunosuppression by CD4+ CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factor β[J].J Exp Med.2001,194(5):629-644
[149]Nakamura K,Kitani A,Fuss I,et al.TGF-β1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice[J].J Immunol.2004,172(2):834-842
[150]Yamagiwa S,Gray JD,Hashimoto S,et al.A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory cells from human peripheral blood[J].J Immunol.2001,166(12):7282-7289
[151]Pyzik M,Piccirillo CA.TGF-betal modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets[J].J Leukoc Biol,2007,82(2):335-346
[152]Strauss L,Bergmann C,Szczepanski M,et al.A unique subset of CD4+CD25 high Foxp3+ T cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment[J].Clin Cancer Res,2007,13(15):4345-4354
[153]Zhang L,Yi H,Xia XP,et al.Transforming growth factor-beta:an important role in CD4+ CD25+ regulatory T cells and immune tolerance[J].Autoimmunity,2006,39(4):269-276
[154]Kawahata K,Misaki Y,Yamauchi M,et al.Generation of CD4+CD25+regulatory T cells from autoreactive T cells simultaneously with their negative selection in the thymus and from nonautoreactive T cells by endogenous TCR expression[J].J Immunol.2002,168 (9):4399-4405
[155]Pacholczyk R,Kraj P,Lgnatowicz L.Peptide specificity of thymic selection of CD4+CD25+T cells[J].J Immunol.2002,168(2):613-620
[156]Sidorenko SP,Clark EA.The dual-function CD 150 receptor subfamily:the viral at reaction[J]. Nat Immunol.2003,4(1):19-24
[157]Okazaki T,Maeda A,Nishimura H,et al.PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine[J].Proc Natl Acad Sci USA,2001,98(24):13866-13871
[158]Balandina A,Lecart S,Dartevelle P,et al.Functional defect of regulatory CD4+CD25+T cells in the thymus of patients with autoimmune myasthenia gravis[J].Blood.2005,105(2):735-741
[159]Lin SC,Chen KH,Lin CH,et al.The quantitative analysis of peripheral blood Foxp3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients[J].Eur J Clin Invest,2007,37(12):987-996
[160]Jiao Z,Wang WJia R,et al.Accumulation of FoxP3-expressing CD4+CD25+T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis[J].Scand J Rheumatol.2007,36(6):428-433
[161]Sakakura M,Wada H,Tawara I,et al.Reduced CD4+CD25+T cells in patients with idiopathic thrombocytopenic purpura[J].Thromb Res.2007,120(2):187-193
[162]Liu B,Zhao H,Poon MC,et al.Abnormality of CD4+CD25+regulatory T cells in idiopathic thrombocytopenic purpura[J].Eur J Haematol.2007,78(2):139-143
[163]Yu J,Heck S,Patel V,et al.Defective circulating CD25 regulatory T cells in patients with chronic immune thrombocytopenic purpura[J].Blood,2008,112(4):1325-1328
[164]赵湜,王红祥,李菁缓,等.调节性T细胞在慢性特发性血小板减少性紫癜中的作用[J].中华血液学杂志,2006,27(3)：203-205
[165]伍昌林,党鑫堂,薛俭成.CD4+CD25+调节性T细胞在ITP患者发病机制中的作用[J].临床输血与检验,2008,10(4)：297-300
[166]舒汨汨,曹星梅,张王刚.CD4+CD25 high T细胞在特发性血小板减少性紫癜发病机制中的作用[J].中国实验血液学杂志,2008,16(4)：875-877
[167]张爱梅,徐修才,王宁玲,等.CD4+CD25+Treg在儿童急性免疫性血小板减少性紫癜发病机制中的作用[J].临床儿科杂志,2009,27(12)：1157-1161
[1]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346 (13): 995-008
[2]陈信义,麻柔,李冬云.规范常见血液病中医病名建议[J].中国中西医结合杂志,2009,29(11)：1040-1041
[3]李宜中.中西医结合治疗急性原发性血小板减少性紫癜的体会[J].天津中医药,1992,(1)：16-17
[4]古学奎,李文晞,胡莉文.丘和明教授治疗特发性血小板减少性紫癜经验介绍[J].新中医,2005,37(10)：7-9
[5]那丽,雍延礼,刘丽梅,等.孙伟正教授治疗原发性血小板减少性紫癜经验[J].中医药信息,2008,25(4)：47～48
[6]周永明,程军.原发性血小板减少性紫癜的病机特点和治疗对策[J].辽宁中医杂志,2001,28(12)：714～715
[7]吴晓勇.傅汝林治疗治疗特发性血小板减少性紫癜经验拾萃[J].辽宁中医杂志,2008,35(11)：1634-1635
[8]曾英坚,于天启,陈志雄.陈志雄教授运用祛风法治疗特发性血小板减少性紫癜经验[J].辽宁中医药大学学报,2008,10(11)：86-87
[9]李芮.焦中华治疗原发性血小板减少性紫癜经验[J].中医杂志,2006,47(8)：579-580
[10]许毅,黄振翘.黄振翘教授调补泻火法治疗难治性特发性血小板减少性紫疲经验介绍[J].新中医,2005,37(9)：12-13
[11]田胜利,姚乃中.姚乃中运用温肾填精、凉血活血法治疗特发性血小板减少性紫癜经验[J].上海中医药杂志,2007,41(6)：12-13
[12]李海燕,陶淑春.陶淑春治疗原发性血小板减少性紫癜的经验[J].辽宁中医杂志,2003,30(1)：16-17
[13]裴明创,王兴丽,阮文让,等.戴锡孟教授治疗原发性血小板减少性紫癜经验[J].天津中医药,2007,24(1)：79-80
[14]周永明,周韶红,黄振翘,等.泻火宁血健脾滋肾法治疗难治性原发性血小板减少性紫癜35例[J].上海中医药杂志,2002,(1)：22-23
[15]袁乃荣,魏学礼,周永明.谈中医治疗特发性血小板减少性紫癜要旨[J].辽宁中医学院学报,2005,7(2)：105-106
[16]傅汝林,刘宏潇,张雅丽.归脾汤加减治疗特发性血小板减少性紫癜68例分析[J].中医药学刊,2002,20(1)：26-27
[17]孙士玲,王祥麒,党辉,等.中药治疗特发性血小板减少性紫癜临床研究[J].辽宁中医杂志,2009,36(1)：73-75
[18]闰桂荣,李岳勃,刘子华.辨证治疗原发性血小板减少性紫癜64例[J].实用中医内科杂 志,2001,15(2)：31-32
[19]潘铭.辨证治疗血小板减少性紫癜123例分析[J].甘肃中医,2001,14(6)：31-32
[20]张艳玲.辩证治疗原发性血小板减少性紫癜[J].华厦医学,2002,15(3)：395-396
[21]叶明.辨证治疗慢性原发性血小板减少性紫癜32例疗效观察[J].北京中医杂志,2002,21(3)：141-142
[22]王丽,柯微君,王玉明,等.免疫性血小板减少性紫癜慢性型88例的分型与治疗[J].北京中医,2003,22(4)：9-1 1
[23]吴秀毅.辩证治疗血小板减少性紫癜[J].实用中医内科杂志,2000,14(3)：36
[24]张金先,王金廷,刘建文.特发性血小板减少性紫癜中医证治法则[J].辽宁中医杂志,2000,27(11)：502
[25]李文梅,赵保丽.活血化瘀法治疗原发性血小板减少性紫癜[J].黑龙江中医药,2000,(1)：10-11
[26]程志,吴艺,陈疏敏,等.中西医结合治疗儿童慢性血小板减少性紫癜36例[J].中医研究,2005,18(10)：45-46
[27]杨文华,高宏,王兴丽.中西医结合治疗慢性特发性血小板减少性紫癜80例[J].辽宁中医杂志,2007,34(8)：1044-1045
[28]陈世明,汪玉芳,刘有平.中西药治疗特发性血小板减少性紫癜85例疗效观察[J].时珍国医国药,2006,17(6)：1056-1057
[29]王龙,向永胜,中西医结合治疗慢性特发性血小板减少性紫癜60例[J].内科,2009,4(6)：881-882
[30]丁丽,吴子茂.中西医结合治疗小儿特发性型血小板减少性紫癜[J].深圳中西医结合杂志,2009,19(5)：295-297
[31]杨宏光,陈志雄,于天启.中西医结合治疗特发性血小板减少性紫癜激素抵抗28例[J].山东中医药大学学报,2007,31(6)：481-482
[32]陈健一,李晓惠,张永健,等,补肾凉血解毒法配合激素治疗特发性血小板减少性紫癜36例[J].四川中医,2006,24(12)：56-57
[33]周红,王沁.中西医祛合治疗小儿原成性血小板减少性紫癜63例疗效观察[J].新中医,2005,37(10)：57-58
[34]罗耀光,刘燕群,胡俊,等.重组炙甘草汤配合小剂量糖皮质激素治疗特发性血小板减少性紫癜的临床观察[J].中国中西医结合杂志,2001,21(7)：501-503
[35]陈育生.环孢菌素A合中药治疗难治性特发性血小板减少性紫癜12例[J].现代中西医结合杂志,2003,12(9)：923-924
[36]周永明,胡明辉,杨镜明,等.生血灵治疗特发性血小板减少性紫癜的临床研究[J].中西医结合学报,2004,2(6)：421-425
[37]甘欣锦,李晓惠,张文曦,等.血可宁治疗特发性血小板减少性紫癜临床观察[J].南京中医药大学学报,2007,23(5)：287-288
[38]刘敏,宋明福,赵为军,等.“生血二号”治疗慢性特发性血小板减少性紫癜36例临床研究[J].四川中医,2008,26(11)：65-66
[39]胡凯文,储真真,陈信义,等.健脾活血方治疗难治性慢性型血小板减少性紫癜的临床观察[J].中国医药学报,2002,17(5)：286-288
[40]郭春兰,孙风.紫茜胶囊治疗特发性血小板减少紫癜120例临床观察[J].黑龙江中医药,2008,(3)：9-10
[41]彭素娟,蒋文明.牛角地黄冲剂治疗慢性难治性特发性血小板减少性紫癜40例总结[J].湖南中医杂志,2007,23(1)：28-29
[42]张永锋,刘立昌,夏洪生.归蓉补血片治疗特发性血小板减少性紫癜2例[J].安徽中医学院学报,2003,22(1)：18-20
[43]代喜平,李达,梁冰.紫癜灵治疗慢性难治性特发性血小板减少性紫癜28例[J].吉林中医药,2005,35(3)：21-23
[44]刘凌,冯莹,庞缨,等.升血小板胶囊治疗特发性血小板减少性紫癜的疗效观察[J].中国医院用药评价与分析,2004,4(4)：233-235
[45]王炜.升血小板胶囊联合强的松治疗特发性血小板减少性紫癜疗效观察[J].浙江中医杂志,2008,43(11)：641-642
[46]于天启,戴微,杨宏光,等.升血小板胶囊为主综合治疗难治性血小板减少性紫癜15例疗效观察[J].新中医,2007,39(3)：31-32
[47]穆迪嘉.益气补血片治疗原发性血小板减少性紫癜的研究[J].中国社区医师(综合版),2007,9(11)：74
[48]罗玲,黄望香.益气补血片联合强的松治疗特发性血小板减少性紫癜的疗效观察[J].现代医药卫生,2007,23(14)：2064-2065
[49]陈世伦,戴红.金薯叶止血合剂(旋甘口服液)用于特发性血小板减少性紫康的疗效观察.第八届全国中西医结合血液病学术会议.中国湖北武汉.2007.第八届全国中西医结合血液病学术会议论文集.194-195
[50]李琦,吴超.血复康治疗原发性血小板减少性紫癜的临床观察[J].浙江中西医结合杂志,2001,11(6)：343-345
[51]诸孟娟.复方皂矾丸联合泼尼松治疗特发性血小板减少性紫癜30例临床观察[J].河北中医,2009,31(12)：1868-1869
[52]杨宇飞,周霭祥,麻柔,等.免疫性血小板减少性紫癜免疫学改变和中医证候分型的关系[J].中国中西医结合杂志,1992,12(5)：263-266
[53]杨宇飞,周霭祥,麻柔.慢性特发性血小板减少性紫癜免疫学改变和中医辨证分型与预后关系初步分析[J].中国中西医结合杂志,1995,17(7)：401-404
[54]杨宇飞,周霭祥,麻柔.养血清癜汤治疗慢性特发性血小板减少性紫癜临床研究[J].中国中西医结合杂志,1999,19(1)：29-33
[55]辛随成,蒋海平,王乙忠.原发性血小板减少性紫癜中医证型与骨髓巨核细胞数量及DNA 值的关系[J].中医杂志,1995,36(2)：101-102
[56]庄海峰,沈建平.特发性血小板减少性紫癜血小板计数巨核细胞计数及形态学分类与中医证候分型的关系[J].中华中医药学刊,2007,25(8)：1681-1684
[57]陈均法,庄海峰.特发性血小板减少性紫癜免疫学改变与中医症候分型的关系[J].中医药学刊,2006,24(5)：890-891
[58]刘静霞,吕瑞民,向莉.清热凉血、益气活血中药治疗原发性血小板减少性紫癜的实验研究[J].中国中医药科技,1997,4(1)：26转60
[59]朱文伟,周永明,薛志忠,等.慢性ITP外周血单个核细胞Thl/Th2亚群反应状态及生血灵干预研究[J].现代中西医结合杂志,2008,17(33)：5120-5121
[60]朱文伟，周永明,袁乃荣,等.特发性血小板减少性紫癜患者GR亚型的表达及生血灵干预研究[J].上海中医药杂志,2010,44(2)：43-45
[61]俞亚琴,孙伟正,孙风,等.补肾化瘀解毒法治疗特发性血小板减少性紫癜的临床研究[J].安徽中医学院学报,2003,22(1)：16-18
[62]俞亚琴,孙伟正,孙风.补肾化瘀解毒法对ITP患者血浆蛋白C和P-选择素的影响.附：60例病例报告[J].成都中医药大学学报,2003,25(1)：13-15
[63]俞亚琴,孙伟正,孙风.补肾化瘀解毒方药对ITP患者血浆β-血小板球蛋白和血小板第4因子影响的研究[J].云南中医学院学报,2003,26(4)：23-24转28
[64]肖咏,冯晶,廖秋源,等,补肾活血方对ITP患儿P-选择素表达的影响及临床疗效观察[J].中医儿科杂志,2008,4(3)：31-33
[65]孙凤,朱云丽.紫茜胶囊对慢性原发性血小板减少性紫癜患者IL-2、sIL-2R的影响[J].中医药信息,2007,24(2)：62-63
[66]刘葛,孙凤.紫茜胶囊对慢性原发性血小板减少性紫癜患者IL-6的影响[J].中医药信息2006,23(6)：48-49
[67]张宇,孙伟正,孙凤.紫茜胶囊对CITP患者骨髓巨核细胞及IL-4的影响关[J].中医药信息,2007,24(4)：62-63
[68]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志,1994,15(3)：160-161
[69]蒋文明,邓常青,陈大舜,等.大鼠免疫性血小板减少模型的研究[J].中国实验动物学报,1996,4(2)：104-108
[70]薛志忠,周永明,方永华,等.免疫性血小板减少家兔模型的实验研究[J].实验血液学杂志,1995,3(3)：334-336
[71]刘宏潇,张雅丽,田维毅.特发性血小板减少性紫癜脾不统血证动物模型建立[J].辽宁中医杂志,2002,29(9)：571-572
[72]杨宇飞,许勇钢,周霭祥,等.免疫性血小板减少性紫癜病证结合肾阴虚动物模型的建立[J].中国中西医结合杂志,1998,18(6)：191-194
[73]蒋文明,陈大舜,邓常青,等.地黄止血冲剂抗大鼠免疫性血小板减少的作用研究[J].中国中 医基础医学杂志,1998,4(9)：30-33
[74]蒋文明,邱赛红,程纬民,等.牛角地黄冲剂对大鼠免疫性血小板减少模型T细胞亚群的影响[J].中国中医基础医学杂志,2002,8(8)：20-21
[75]蒋文明,邱赛红,胡志光,等.牛角地黄冲剂对免疫性血小板减少大鼠血浆血栓素A2、前列环素I2影响的实验研究[J].中国中医药科技,2003,10(5)：271-272
[76]傅汝林,刘为民,张雅丽,等.归脾冲剂对免疫性血小板减少性紫癜动物模型实验研究[J].中医药学刊,2001,19(4)：312-313
[77]马骥,陶淑春,范颖.一种治疗免疫性血小板减少性紫癜的中药及其生产方法[P].中国专利：200610135073.7,2007-08-15
[78]王缨,夏卫军.加味小柴胡颗粒及其组方对ITP模型小鼠造血系统的影响[J].中华中医药学刊,2008,26(1)：106-108
[79]王缨,夏卫军.加味小柴胡颗粒及其组方对ITP模型小鼠免疫功能的影响[J].中国免疫学杂志,2008,24(2)：131-134
[80]王缨,夏卫军.加味小柴胡颗粒对免疫性血小板减少性紫癜下丘脑-垂体-肾上腺系统的影响[J].北京中医药大学学报,2008,31(8)：553-556
[81]王缨,夏卫军.原发性血小板减少性紫癜模型小鼠血浆内皮素水平与加味小柴胡颗粒及其组方的干预[J].中国组织工程与临床康复,2007,11(33)：6597-6599
[82]孙凤,韩晶,郭春兰,等.紫茜胶囊对原发性血小板减少性紫癜鼠外周血的影响研究[J].中医药信息,2006,23(1)：61-62
[83]王景,郭春兰,孙凤.紫茜胶囊对ITP模型小鼠外周血血小板相关抗体的影响[J].中医药信息,2006,23(5)：70-72
[84]郭春兰,孙凤,王景.紫茜胶囊对ITP模型小鼠外周血细胞因子IL-2及其受体的影响[J].中医药信息,2008,23(5)：58-59
[85]徐平声,李新可,潘善庆,等.西蒙胶囊对兔与大鼠免疫性血小板减少的保护作用[J].中南药学,2006,4(6)：418-450
[86]李健哲,徐平声,李元建.西蒙醇提取物对家兔特发性血小板减少性紫癜白细胞介素-4和干扰素-γ的影响[J].中南药学,2009,7(1)：2-4
[1]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346(13): 995-008
[2]Arnott J,Horsewood P,Kelton JGMeasurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia[J].Blood,1987,69(5):1294-1299
[3]Stenberg PE,Levin J,Corash L.Sustained thrombocytopenia in mice:serial studies of mega-karyocytes and platelets[J].Exp Hematol.1990,18(2):124-132
[4]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志,1994,15(3)：160-161
[5]Alves-Rosa F,Stanganelli C,Cabrera J,et al.Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model[J].Blood,2000,96(8):2834-2840
[6]朱立平,陈学清.免疫学常用实验方法[M].北京：人民军医出版社,2000.1-2,15-22,352-355
[7]富琦,范颖,王家辉,等.免疫性血小板减少性紫癜病证结合动物模型建立与评价[J].中国中医基础医学杂志.2004,10(2)：30-32
[8]Wei H,Ding X,Ren J,et al.A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen[J].J Genet Genomics.2008,35(11):665-671
[9]Iki S,Urabe A.Refractory idiopathic thrombocytopenic purpura[J].Nippon Rinsho.2003,61(4): 609-614
[10]Cines DB, Bussel JB, McMillan RB,et al.Congenital and acquired thrombocytopenia[J]. Hematology(Am Soc Hematol Educ Program).2004:390-406
[11]McKenzie SE,Reilly MP.Heparin-induced thrombocytopenia and other immune thrombocyto-penias:lessons from mousemodels[J].Semin ThrombHemost,2004,30(5):559-568
[12]Meade CJ,Heuer H,Kempe R.Biochemical pharmacology of platelet activating factor(and PAF antagonists) in relation to clinical and experimental thrombocytopenia[J].Biochem Pharmacol, 1991,41 (5):657-668
[13]Kuter DJ,Rosenberg RD.The reciprocal relationship of thrombopoietin(c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit [J].Blood, 1995,85(10):2720-2730
[14]Ashida SI, Abiko Y.Protective effect of pantethine on experimental thrombocytopenia in the rat[J].Thromb Diath Haemorrh,1975,33 (3):528-539
[15]Oyaizu N,Yasumizu R,Miyama-Inaba M,et al.(NZW x BXSB) F1 mouse.A new animal model of idiopathic thrombocytopenic purpura[J].J Exp Med,1988,167(6):2017-2022
[16]Hosono M,Sone N,Endo K,et al.Kinetics of platelets in dogs with thrombocytopenia induced by antiglycoprotein Ilb/IIIa receptor monoclonal antibody[J].Nucl Med Biol,1995; 22 (1):71-76
[17]Coetzee LM,Pieters H,van Wyk V,et al.The effect of monoclonal anti-human-platelet anti-bodies on platelet kinetics in a baboon model:IgG subclass dependency[J].Thromb Haemost,2000, 83(1):148-156
[18]Nieswandt B,Bergmeier W,Rackebrandt K,et al.Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice [J].Blood,2000; 96(7):2520-2527
[19]Harrington WJ,Minnich V,Hollingseorth JW,et al.Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura[J]. J Lab Clin Med,1951,38:1-10
[20]Bentfeld ME,Bainton DF.Cytochemical localization of lysosomal enzymes in rat megakaryo-cytes and platelets[J].J Clin Invest.1975,56(6):1635-1649
[21]Mizutani H,Engelman RW,Kurata Y,et al.Development and characterization of monoclonal antiplatelet autoantibodies from autoimmune thrombocytopenic purpura-prone (NZW X BXSB)F1m ice[J].Blood,1993,82(3):837-844
[22]Crow AR,Song S,Freedman J,et al.IVIg mediated amelioration of murine ITP via FcR ⅡB is independent of SHIP 1,SHP-1,and Btk activity[J].Blood,2003,102:558-560
[23]Karassa FB, Trikalinos TA, Ioannidis JP. The role of Fc γRⅡA and Ⅲ A polymorphisms in autoimmune diseases[J].Biomed Pharmacother,2004,58:286-291
[24]McKenzie SE, Taylor SM, M alladi P, et al.The role of the human Fc receptor/Fc γ RⅡA in the immune clearance of platelets:a transgenic mouse model[J]J Immunol,1999,162:4311-4318
[25]McKenzie SE.Humanized mouse models of FcR clearance in immune platelet disorders [J].Blood Rev,2002,16:3-5
[26]Mason 1, Carpinelli MR, Fletcher JL, et al.Programmed anuclear cell death delimits platelet life span[J].Cell,2007,128(6):1173-1186
[27]Liu Z,Gurlo T,von Grafenstein H.Cell-ELISA using beta-galactosidase conjugated antibodies [J].J Immunol Methods,2000,234(1-2):153-167
[28]Salih AM,Nixon NB,Dawes PT,et al.Antibodies to neuroblastoma cells in rheumatoid arthritis: a potential marker for neuropathy[J].Clin Exp Rheumatol,2000,18(1):23-30
[29]Lee JC,Cevallos AM, NaeemA,et al.Detection of anti-colon antibodies in inflammatory bowel disease using human cultured colonic cells[J].Gut,1999,44(2):196-202
[1]Arnott J, Horsewood P, Kelton JGMeasurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia[J].Blood,1987,69(5):1294-1299
[2]Stenberg PE,Levin J,Corash L.Sustained thrombocytopenia in mice:serial studies of mega-karyocytes and platelets[J].Exp Hematol.1990,18(2):124-132
[3]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志.1994,15(3)：160-161
[4]Alves-Rosa F,Stanganelli C,Cabrera J,et al.Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model[J].Blood,2000,96(8):2834-2840
[5]富琦,范颖,王家辉,等.免疫性血小板减少性紫癜病证结合动物模型建立与评价[J].中国中医基础医学杂志.2004,10(2)：30-32
[6]Wei H,Ding X,Ren J,et al.A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen[J]J Genet Genomics.2008,35(11):665-671
[7]许亚梅,姜苗,陈信义.益髓颗粒剂在现代难治血液病中的应用[J].中国医药学报,2004,19(4)：245-246
[8]李冬云,马薇,荣秀梅,等.益髓颗粒组方分析及应用研究[J].中外医疗,2009,(8)：153-154
[9]van Leeuwen EF,van der Ven JT,Engeffriet CP,et al.Specificity of autoantibodies in auto-immune thrombocytopenia[J].Blood,1982,59(l):23-26
[10]McMillan R.Autoantibodies and autoantigens in chronic immune thrombocytopenia purpura [J].Semin Hematol.2000,37:239-248
[11]Fujisawa K,Tani P, OToole TE,et al.Different specificities of platelet-associated and plasma autoantibodies to platelet GPIIb-IIIa in patients with chronic immune thrombocytopenic purpura[J].Blood,1992,79(6):1441-1446
[12]Kiefel V,Santoso S,Kaufmann E,et al.Autoantibodies against platelet glycoprotein Ib/IX:a frequent finding in autoimmune thrombocytopenic purpura[J].Br J Haematol.1991,79(2):256-262
[13]Hou M,Stockelberg D,Kutti J,et al.Antibodies against platelet GPⅠb/IX,GPⅡb/Ⅲa,and other platelet antigens in chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol.1995,55(5): 307-314
[14]Kiefel V, Freitag E, Kroll H, et al.Platelet autoantibodies (IgQ IgM, IgA) against glyco-proteins Ⅱb/Ⅲa and Ⅰb/Ⅸ in patients with thrombocytopenia[J].Ann Hematol.1996,72(4):280-285
[15]Saleh MN,Moore DL,Lee JY,et al. Monocyte-platelet interaction in immune and non-immune thrombocytopenia[J].Blood,1989,74(4):1328-1331
[16]Semple JW.Immune pathophysiology of autoimmune thrombocytopenic purpura[J].Blood rev, 2002,16(1):9-12
[17]McMillan R.The Pathogenesis of Chronic Immune Thrombocytopenic Purpura[J]. Semin Hematol,2007,44(Suppl 5):S3-S11
[18]Chang M,Nakagawa PA,Williams SA,et al.Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro[J].Blood,2003, 102(3):887-895
[19]McMillan R,Wang L,Tomer A,et al.Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP[J].Blood,2004,103 (4):1364-1369
[20]侯明.成人特发性血小板减少性紫癜诊断治疗专家共识[J].中华血液学杂志,2009,30(9)：647-648
[21]Jubelirer SJ,Harpold R.The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura:case series and literature review[J].CIin Appl Thromb Hemost,2002, 8(1):73-76
[22]Wang ZY,Shen ZX.Megakaryocytes and platelets in immune thrombocytopenic purpura [J]. Baillieres Clin Haematol.1997,10(1):89-107
[23]唐雪梅,唐晓兰,何文华,等.特发性血小板减少性紫癜90例骨髓与疗效分析[J].四川医学,2002,23(2)：177
[24]British Committee for Standards in Haematology General Haematology Task Force. Guide-lines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J].Br J Haematol,2003,120(4):574-596
[25]朱雪明,顾志成,王兴东.儿童特发性血小板减少性紫癜脾脏组织的病理形态学研究[J].临床小儿外科杂志,2005,4(4)：259-262转265
[1]Arnott J,Horsewood P,Kelton JGMeasurement of platelet-associated IgG in animal models of immune and nonimmune thrombocytopenia[J].Blood,1987,69(5):1294-1299
[2]Stenberg PE,Levin J,Corash L. Sustained thrombocytopenia in mice:serial studies of mega-karyocytes and platelets[J].Exp Hematol.1990,18(2):124-132
[3]杨宇飞,周霭祥,麻柔.免疫性血小板减少性紫癜动物模型的建立[J].中华血液学杂志,1994,15(3)：160-161
[4]Alves-Rosa F, Stanganelli C, Cabrera J, et al. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model[J].Blood,2000,96(8):2834-2840
[5]富琦,范颖,王家辉,等.免疫性血小板减少性紫癜病证结合动物模型建立与评价[J].中国中医基础医学杂志.2004,10(2)：30-32
[6]Wei H,Ding X,Ren J,et al.A murine model for human immune thrombocytopenic purpura and comparative analysis of multiple gene expression in bone marrow and spleen[J].J Genet Genomics.2008,35(11):665-671
[7]张谊之,王琳,陈娘,等.白塞病皮损中淋巴细胞凋亡和Fas、 Bcl-2的表达[J].临床皮肤科杂 志.2002,3 1(2)：72-74
[8]Mosmann TR,Sad S.The expanding universe of T-cell subsets:Thl,Th2 and more[J]. Immunol Today.1996,17(3):138-146
[9]Romangnani S.Th1 and Th2 in human diseases[J].Clin Immunol Immunopath.1996,80(3):225-235
[10]Newton C, Klein T, Friedman H.The role of macrophages in THC-induced alteration of the cytokine network[J].Adv Exp Med Biol,1998,437:207-214
[11]Haggqvist B, Hultman P.Effects of deviating the Th-2 response in murine mercury-induced autoimmunity towards a Thl-response[J].Clin Exp Immunol,2003,134(2):202-209
[12]Mosmann TR,Kobie JJ,Lee FEH,et al.T helper cytokine patterns:defined subsets, random expression, and external modulation[J].Immunol Res.2009,45:173-184
[13]Nakamura T,Lee RK,Nam SY, et al. Roles of IL-4 and IFN-gamma in stabilizing the T helper cell type 1 and2 phenotype[J].JImmunol,1997,158(6):2648-2653
[14]Maneti R,Parrinchi P,Giudizi M,et al.Natural killer cell stimulatory factor (Interleukin-12[IL-12]) induces T helper type1(Thl)-specific immune responses and inhibitis the development of IL-4 producing Th cells[J].J Exp Med,1993,177(4):1199-1204
[15]魏海明,刘志,田志刚,等.检测Th1/Th2亚群的意义[J].中华医学检验杂志.1998,21(1)：56-59
[16]陈素娟,孙晓丽,董晓军,等.白细胞介素-4生物学功能及其临床应用[J].标记免疫分析与临床,2003,10(1)：37-39
[17]龚非力主编.医学免疫学[M].第2版.北京：科学出版社,2004.61-84
[18]Cines DB,Blanchette VS.Immune thrombocytopenic purpura[J].N Engl J Med,2002,346(13): 995-1008
[19]McMillan R.The Pathogenesis of Chronic Immune Thrombocytopenic Purpura[J].Semin Hematol,2007,44(Suppl 5):3-11
[20]Zhou B,Zhao H,Yang RC,et al.Multi-dysfunctional pathophysiology in ITP[J].Crit Rev Oncol Hematol,2005,54(2):107-116
[21]Cooper N,Bussel J.The pathogenesis of immune thrombocytopaenic purpura[J].Br J Haematol, 2006,133(4):364-374
[22]Chanock S.The etiology of childhood immune thrombocytopenic purpura:how complex is it?[J].J Pediatr Hematol Oncol,2003,25(Suppl 1):S7-10
[23]Mouzald A,Theodoropoulou M,Gianakopoulos I,et al.Expression patterns of Thl and Th2 cytokine genes in childhood idiopathic thrombocytopenic purpura(ITP) at presentation and their modulation by intravenous immunoglobulin G(ⅣIg) treatment:their role in prognosis[J].Blood, 2002,100(5):1774-1779
[24]Panitsas FP,Theodoropoulou M,Kouraklis A,et al.Adult chronic idiopathic thrombocytopenic purpura(ITP) is the manifestation of a type-1 polarized immune response[J].Blood,2004,103 (7):2645-2647
[25]Ogawara H, Handa H, Morita K,et al. High Thl/Th2 ratio in patients with chronic idiopathic thrombocytopenic purpura[J].Eur J Haematol,2003,71(4):283-288
[26]Semple JW,Milev Y,Cosgrave D,et al.Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura:relationship to platelet phenotype and antiplatelet T-cell reactivity[J].Blood,1996,87(10):4245-4254
[27]Panitsas FP,Kouraklis A.Effect of splenectomy on type-1/type-2 cytokine gene expression in a patient with adult idiopathic thrombocytopenic purpura (ITP)[J].BMC Blood Disord,2004,4(1):4
[28]王宁玲,戴海明,祝怀平,等.特发性血小板减少性紫癜患儿Thl/Th2相关细胞因子的检测[J].中华血液学杂志,2002,23(9)：486-487
[29]阮积晨,赵芹,周海霞,等.特发性血小板减少性紫癜患儿Th亚群细胞因子的检测[J].中国小儿血液与肿瘤杂志,2006,11(4)：22-24
[30]杨小猛,刘仿,陈群,等.特发性血小板减少性紫癜患儿Thl/Th2、Tc1/Tc2亚群漂移的研究[J].中国免疫学杂志,2005,21(1)：76-79
[31]Crossley AR,Dickinson AM,Proctor SJ,et al.Effects of interferon-a therapy on immune parameters in immune thrombocytopenic purpura[J].Autoimmunity.1996,24(2):81-100
[32]Webber NP,Mascarenhas JO,Crow MK,et al. Functional properties of lymphocytes in idiopathic thrombocytopenic purpura[J].Hum Immunol.2001,62(12):1346-1355
[33]王国兵,李成荣,李长钢,等.儿童急性ITP Th1/Th2细胞功能状态初步研究[J].中国小儿血液与肿瘤杂志,2008,13(4)：156-160
[34]Letterio JJ,Roberts AB.Regulation of immune responses by TGF-beta[J].Ann Rev Immunol, 1998,16:137-161
[35]Fukaura H, Kent SC, Pietrusewicz MJ,et al.Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-betal-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients[J].Journal of Clinical Investigation, 1996,98(1):70-77
[36]Bridoux F,Badou A,Saoudi A,et al.Transforming growth factor-β(TGF-β)-dependent inhibition of T helper cell 2 (Th2)-induced autoimmunity by self-major histocompatibility complex(MHC) class II-specific,regulatory CD4+T cell lines[J].J Exp Med,1997,185(10):1769-1775
[37]Chen Y, Kuchroo VK,Inobe J,et al.Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis[J].Science,1994,265(5176):1237-1240
[38]Cross D,Cambier JC.Transforming growth factor beta-1 has differential effects on B cell proliferation and activation antigen expression[J].J Immunol,1990,144:432-439
[39]Gorelik L.Flavell RA. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease[J].Immunity,2000,12(2):171-181
[40]Fortunel N,Hatzfeld J,Kisselev S,et al.Release from quiescence of primitive human hemato- poietic stem/progenitor cells by blocking their cell-surface TGF-beta type Ⅱ receptor in a short-term in vitro assay[J].Stem Cells,2000,18(2):102-111
[41]Atabay B,Oren H,Irken Qet al.Role of transforming growth factor-beta 1 gene polymerphisms in childhood idiopathic thrombocytopenic purpura[J].J Pediatr Hematol Oncol,2003,25(11):885-889
[42]Fortunel NO,Hatzfeld A,Hatzfeld JA.Transforming growth factor-beta:pleiotropic role in the regulation of hematopoiesis[J].Blood,2000,96(6):2022-2036
[43]Sakamaki S,Hirayama Y,Matsunaga T,et al.Transforming growth factor-β1(TGF-β1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-(3 receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-P itself with high specificity[J].Blood,1999,94(6):1961-1970
[44]鞠秀丽,丁红芳,魏伟,等.血小板生成素和转化生长因子-β1与儿童特发性血小板减少性紫癜的相关性研究[J].中国实用儿科杂志,2004,19(11)：663-665
[45]Andersson PO, Stockelberg D, et al. A transforming growth factor-betal-mediated bystander immune suppression could be associated with remission of chronic idiopathic thrombocytopenic purpura[J].Ann Hematol,2000,79(9):507-513
[46]Fahim NM, Monir E.Functional role of CD4+CD25+regulatory T cells and transforming growth factor-betal in childhood immune thrombocytopenic purpura[J].Egypt J Immunol.2006, 13(1):173-187
[47]Sakaguchi S,Sakaguchi N,Asano M,et al.Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains(CD25).Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases[J]. J Immunol.1995,155 (3):1151-1164
[48]Picca CC, Caton AJ.The role of self-peptides in the development of CD4+CD25+regulatory T cells[J].Curr Opin Immunol,2005,17(2):131-136
[49]Piccirillo CA, Thornton AM. Cornerstone of peripheral tolerance:naturally occurring CD4+CD25+regulatory T cells[J].Trends Immunol,2004,25(7):374-380
[50]Sakaguchi S, Sakaguchi N,Shimizu J,et al.Immunologic tolerance maintained by CD4+CD25+ regulatory T cells:their common role in controlling autoimmunity,tumor immunity,and trans-plantation tolerance[J].Immunol Rev,2001,182(1):18-32
[51]Lan RY,Ansari AA,Lian ZX,et al.Regulatory T cells:development,function and role in auto-immunity [J].Autoimmu Rev,2005,4(6):351-363
[52]Hori S, Nomura T, Sakaguchi S.Control of regulatory T cell development by the transcription factor Foxp3[J].Science,2003,299(5609):1057-1061
[53]Fontenot JD,Gavin MA,Rudensky AYFoxp3 programs the development and function of CD4+CD25+regulatory T cells[J].Nat Immunol,2003,4(4):330-336
[54]Shevach EM.Certified professionals:CD4+CD25+suppressor T cells[J].J Exp Med.2001,193 (11):F41-45
[55]Thompson C,Powrie F.Regulatory T cells[J].Curr Opin Pharmacol.2004,4(4):408-414
[56]Sakaguchi S,Yamaguchi T,Nomura T,et al.Regulatory T Cell and Immune Tolerance[J].Cell, 2008,133(5):775-787
[57]Taams LS,van Amelsfort JM,Tiemessen MM,et al.Modulation of monocyte/macrophage function by human CD4+CD25+regulatory T cells[J].Hum Immunol.2005,66(3):222-230
[58]Chatila TA.Role of regulatory T cells in human diseases[J].J Allergy Clin Immunol,2005,116 (5):949-959
[59]Sakaguchi S.Naturally arising CD4+regulatory T cells for immunologic self-tolerance and negative control of immune responses[J].Allnu Rev Immunol,2004,22:531-562
[60]Horwitz DA,Zheng SQGray JD.The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+CD25+ and CD8+ regulatory T cells subsets [J].Leukoc Biol,2003,74(4):471-478
[61]Cederbom L,Hall H,Ivars F.CD4+CD25+regulatory T cells down-regulate co-stimuatory molecules on antigen-presenting cells[J].Eur J Immunol,2000,30(6):1538-1543
[62]Kursar M,Bonhagen K,Fensterle J,et al.Regulatory CD4+CD25+T cells restrict memory CD8+T cell responses[J].J Exp Med,2002,196(12):1585-1592
[63]Azuma T,Takahashi T,Kunisato A,et al.Human CD4+CD25+regulatory T cells.suppess NKT cell fiinction[J].Cancer Res,2003,63(15):4516-4520
[64]Lim HW,Hillsamer P,Banham AH,et al.Cutting edge:Direct suppression of B cells by CD4+CD25+regulatory T cells[J].J Immunol,2005,175(7):4180-4183
[65]Zhao DM,Thornton AM,Dipaolo RJ,et al.Activated CD4+CD25+T cells selectively kill B lymphocytes[J].Blood,2006,107(10):3925-3932
[66]Hsu WT,Suen JL,Chiang BL.The role of CD4+D25+T cells in autoantibody production in murine lupus[J].Clin Exp Immunol,2006,145(3):513-519
[67]何伟刚,曹雪涛.CD4+CD25+调节性T细胞与负向免疫调控及免疫耐受[J].国际肿瘤学杂志,2006,33(5)：324-328
[68]Balandina A,Lecart S,Dartevelle P,et al.Functional defect of regulatory CD4+CD25+T cells in the thymus of patients with autoimmune myasthenia gravis[J].Blood,2005,105 (2):735-741
[69]Lin SC,Chen KH,Lin CH,et al.The quantitative analysis of peripheral blood Foxp3-expressing T cells in systemic lupus erythematosus and rheumatoid arthritis patients[J].Eur J Clin Invest,2007,37(12):987-996
[70]Jiao Z,Wang WJia R,et al.Accumulation of Foxp3-expressing CD4+CD25+T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis [J].Scand J Rheumatol.2007,36(6):428-433
[71]Kemeny DM, Macary PA.The growing complexity of TGF-beta as a T-cell regulator [J]. Immunology,2005,114(4):459-460
[72]Nakamura K,Kitani A,Strober W.Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T cells is mediated by cell surface-bound transforming growth factorβ[J] J Exp Med. 2001,194(5):629-644
[73]Nakamura K,Kitani A,Fuss I,et al.TGF-β1 plays an important role in the mechanism of CD4+CD25+regulatory T cell activity in both humans and mice[J].J Immunol.2004,172(2): 834-842
[74]Huber S,Schramm C.TGF-beta and CD4+CD25+regulatory T cells[J].Front Biosci,2006,11 (1):1014-1023
[75]Yamagiwa S,Gray JD,Hashimoto S,et al.A role for TGF-beta in the generation and expansion of CD4+CD25+regulatory cells from human peripheral blood[J].J Immunol.2001,166(12): 7282-7289
[76]Pyzik M,Piccirillo CA.TGF-betal modulates Foxp3 expression and regulatory activity in distinct CD4+T cell subsets[J].J Leukoc Biol,2007,82(2):335-346
[77]Strauss L,Bergmann C,Szczepanski M,et al.A unique subset of CD4+CD25 high Foxp3+T Cells secreting interleukin-10 and transforming growth factor-β1 mediates suppression in the tumor microenvironment[J].Clin Cancer Res,2007,13(15):4345-4354
[78]Von Boehmer H.Mechanisms of suppression by suppressor T cells[J].Nat Immunol,2005,6(4): 338-344
[79]Zhang L,Yi H,Xia XP,et al.Transforming growth factor-beta:an important role in CD4+CD25+ regulatory T cells and immune tolerance[J].Autoimmunity,2006,39(4):269-276
[80]Sakakura M,Wada H,Tawara I,et al.Reduced CD4+CD25+T cells in patients with idiopathic thrombocytopenic purpura[J].Thromb Res.2007,120(2):187-193
[81]Liu B,Zhao H,Poon MC,et al.Abnormality of CD4+CD25+regulatory T cells in idiopathic thrombocytopenic purpura[J].Eur J Haematol.2006,78(2):139-143
[82]Pinkoski MJ,Waterhous NJ,Green DR. Mitochondria,apoptosis and autoimmunity[J].Curr Dir Autoimmun,2006,9:55-73
[83]Perfettini JL,Roumier T,Kroemer GMitochondrial fusion and fission in the control of apoptosis [J].Trends Cell Biol,2005,15(4):179-183
[84]Derfuss T,Fickenscher H,Kraft MS,et al.Antiapoptotic activity of the herpervirus saimiri-encoded Bcl-2 homolog:stabilization of mitochondria and inhibition of caspase-3-like activity [J].J Virol,1998,72(7):5897-5904
[85]Adams JM,Cory S.The Bcl-2 protein family:Abiters of cell survival[J].Science,1998,281 (5381):1322-1326
[86]Petros AM,Olejniczak ET,Fesik SW.Structural biology of the Bcl-2 family of proteins[J]. Biochim Biophys Acta,2004,1644(2-3):83-94
[87]Cosulich SQWorrall V,Hedge PJ,et al.Regulation of apoptosis by BH3 domains in a cell-free system[J].Curre Biol,1997,71(12):913-920
[88]Breckenridge DG, Xue D.Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases[J].Curr Opin Cell Biol,2004,16(6):647-652
[89]Sharpe JC, Arnoult D,Youle RL.Crontrol of mitochondrial permeability by Bcl-2 family members[J].Biochim Bionhys Acta,2004,1644(2-3):107-113
[90]Rosse T,Olivier R,Monney L,et al.Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c [J].Nature.1998,391(6666):496-499
[91]周桔,罗荣保,汤长发,等.Bcl-2蛋白家族和p53基因在细胞凋亡中的调控效应[J].中国组织工程研究与临床康复,2007,11(10)：1950-1952
[92]Kuwana,Newmeyer.Bcl-2 family proteins and the role of mitochondria in apoptosis[J]. Curr Opin Cell Biol,2003,15(4):691-699
[93]Lalier L,Cartron PF,Juin P,et al.Bax activation and mitochondrial insertion during apoptosis[J]. Apoptosis,2007,12(5):887-896
[94]Korsmeyr SJ.Bcl-2 gene family and the regulation of programmed cell death[J].Cancer Res.1999,59(7Suppl):1693-1700
[95]Eguchi K.Apoptosis in autommune diseases[J].Inter Med.2001,40(4):275-284
[96]Olsson B, Andersson PO,Jacobsson S,et al.Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura[J].Thromb Haemost.2005,93(1):139-144
[97]Wu CL,Liu F,Zhou XM,et al.Effect of protein kinase C on proliferation and apoptosis of T lymphocytes in idiopathic thrombocytopenic purpura children[J].Cell Mol Immunol,2005,2(3): 197-203
[98]Liu F,Wu CL,Yang XM,et al.Polarization and apoptosis of T cell subsets in idiopathic thrombocytopenic purpura[J].Cell Mol Immunol.2005,2(5):387-392
[99]刘仿,肖红,孟琼,等.特发性血小板减少性紫癜淋巴细胞凋亡及凋亡蛋白表达的研究[J].中国免疫学杂志.2004,20(3)：202-205
[100]Yoshimura C,Nomura S,Nagaham M,et al.Plasma-soluble Fas (APO-1、CD95) and soluble Fas ligand in immune thrombocytopenic purpura[J].Eur J Haematol,2000,64(4):219-224
[101]王开颜,房崇芸,彭光洁.氢化可的松诱导特发性血小板减少性紫癜淋巴细胞凋亡和增殖抑制[J].中国组织化学与细胞化学杂志,2000,9(2)：149-151